

*PBS
Expenditure
and
Prescriptions
Report
1 July 2019
to
30 June 2020*

*PBS Information Management Section
Pricing and PBS Policy Branch
Technology Assessment and Access Division*

This publication and previous editions can be accessed via the internet:
<http://www.pbs.gov.au/info/browse/statistics>

Please direct enquiries or feedback to:

Surface mail: Director
PBS Information Management Section
Pricing and PBS Policy Branch, MDP 900
Department of Health
GPO Box 9848 Canberra ACT 2601

E-mail: pbsstats@health.gov.au

Important Information

Unless otherwise indicated this publication has been produced using data provided to the Department of Health by the Services Australia. The figures reported in this publication relate to the value (benefit) or volume of PBS prescriptions that have been processed by the Services Australia. They refer only to paid services processed for prescriptions submitted and claimed via the PBS Online claiming system by the approved suppliers. Claims of manually processed PBS programs are excluded.

PBS Expenditure includes the following patient categories:

- General - Non-Safety Net (Ordinary)
- General - Safety Net
- Concessional - Non-Safety Net (Ordinary)
- Concessional - Safety Net
- Doctor's Bag

The financial information in this publication is presented on a cash (expenditure) basis, except where indicated otherwise.

The patient category refers to the patient's eligibility status at the time of supply of the benefit. General patients hold a Medicare card, Concessional patients hold a Medicare card and one of the following cards from Centrelink:

- Pension Concession Card
- Commonwealth Seniors Health Card
- Health Care Card

There are two safety net thresholds – one for General patients and the other for Concessional patients.

From 1 January 2020, the general patient safety net threshold was **\$1,486.80**. When patients and/or their families reached this amount, they could apply for a Safety Net Card and pay only **\$6.60** per prescription for the rest of the calendar year. The concessional safety net threshold was **\$316.80**. Once patients and/or their families reached this amount, they could apply for a Safety Net Entitlement Card and receive items free of charge for the rest of the calendar year.

The Patient Contribution, Total Cost and Average Price amounts do not include brand or therapeutic premiums.

From 2016-17 this publication is based on the date that a prescription medicine was supplied to a patient. Previous publications were based on the date that a claim was processed (and the payment finalised) by the Services Australia. The historical data from 1948-49 to 2015-16 on pages 27 to 32 remains by date of processing.

Caution should be exercised in referring to the breakdown by patient category in Table 21(a) on pages 27 to 28 and Table 21(b) on pages 29 to 32, because of a past problem in data supplied by the Services Australia whereby a number of General Safety Net scripts were wrongly allocated to Concessional Non-Safety Net. This problem was fixed for 2008-09, but the 2006-07 and 2007-08 allocations of scripts and expenditure by patient category were

inaccurate and not strictly comparable to the corresponding 2008-09 and later years' numbers.

While Section 100 data has been included in the majority of tables in this report, this data does not include supplies to Aboriginal Health Services with the exception of Tables 1(a) and 1(b) on page 1.

Expenditure on nusinersen was adjusted to include manual payments that were not processed through the PBS Online system.

The Department of Health has taken every care to ensure the data supplied is accurate but does not warrant that the data is error free and does not accept any liability for errors or omissions in the data.

Summary of Pharmaceutical Benefits Scheme 2019-2020

Total Pharmaceutical Benefits Scheme (PBS) Government expense for the supply of medicines under Section 85 and Section 100 on an accrual accounting basis for the 2019-2020 financial year was **\$12,614 million** (excluding revenue), compared with **\$11,818 million** for the previous year. This is an increase of **6.7%**.

The majority of the Expenditure and Prescriptions report refers to PBS Section 85 and Section 100 data reported by financial year (based on date of supply); however, a few tables refer to Section 85 only and some tables report pharmacy program expenditure.

Total 2019-20 PBS subsidised prescription volume increased by **1.6%** to a total of **208.5 million**, compared to 205.1 million for the 2018-19 financial year.

In 2019-20, PBS Government expenditure on a cash accounting basis for the supply of medicines under Section 85 and Section 100 was **\$12,507 million** (excluding rebates) which is **89.2%** of the total cost of PBS prescriptions. The remainder was patient contributions, which amounted to **\$1,520 million**.

The majority of Government expenditure in 2019-20 on PBS Section 85 and Section 100 prescriptions was directed towards concessional cardholders (**\$8,253 million, 66.0% of the total**), compared to concessional cardholders expenditure for 2018-19 (**\$7,777 million, 66.5%** of the total).

The average dispensed price (Patient payment plus Government benefit) per prescription of PBS subsidised medicines increased to **\$67.34** in 2019-20, compared to **\$64.33** in 2018-19.

There were **902** different medicines in **5,371** brands listed on the PBS as at 30 June 2020.

List of tables

Table	Description	Page
Table 1(a)	PBS Expense on an Accrual Accounting Basis, 2018-19 and 2019-20	1
Table 1(b)	PBS Section 100 Programs on an Accrual Accounting Basis, 2018-19 and 2019-20	1
Table 2(a)	PBS Prescriptions, 2018-19 and 2019-20 (incl. under co-pay prescriptions)	2
Table 2(b)	PBS Government Cost, 2018-19 and 2019-20 (excl. under co-pay prescriptions)	2
Table 2(c)	RPBS and PBS Subsidised Prescriptions for DVA patients, 2018-19 and 2019-20 (excl. under co-pay prescriptions)	2
Table 2(d)	RPBS and PBS Government Cost for DVA patients, 2018-19 and 2019-20 (excl. under co-pay prescriptions)	2
Table 3(a)	PBS Section 85 Subsidised Prescriptions, Government Cost, Patient Contribution and Average Price, 2019-20 (excl. under co-pay prescriptions)	3
Table 3(b)	PBS Subsidised Prescriptions, Government Cost, Patient Contribution and Average Price, 2019-20 (excl. under co-pay prescriptions)	3
Table 3(c)	PBS Prescriptions, Government Cost, Patient Contribution and Average Price by Month of Supply, 2018-19 and 2019-20 (excl. under co-pay prescriptions)	3
Table 4	PBS Subsidised Prescriptions by Pharmacy State, 2019-20 (excl. under co-pay prescriptions)	4
Table 5(a)	Top 50 PBS Drugs (by Active Ingredient) Sorted by Highest Government Cost, 2019-20 (excl. under co-pay prescriptions)	5
Table 5(b)	Top 50 PBS Drugs (by Active Ingredient) Sorted by Highest Subsidised Prescriptions, 2019-20 (excl. under co-pay prescriptions)	6
Table 5(c)	Top 25 PBS Cancer Drugs (by Active Ingredient) Sorted by Highest Government Cost, 2019-20 (excl. under co-pay prescriptions)	7
Table 5(d)	Top 25 PBS Biologic Drugs (by Active Ingredient) Sorted by Highest Government Cost, 2019-20 (excl. under co-pay prescriptions)	7
Table 6	Top 50 PBS Drugs (by Active Ingredient) Sorted by Highest Total Prescription Volume, 2019-20 (incl. under co-pay prescriptions)	8
Table 7	Top 50 ATC Level 2 Drug Groups Sorted by Highest Total Prescription Volume, 2019-20 (incl. under co-pay prescriptions)	9
Table 8	ATC Main Groups Comparison for PBS Subsidised Prescriptions, Government Cost, Patient Contribution and Average Price, 2018-19 and 2019-20 (excl. under co-pay prescriptions)	10
Table 9(a)	Top 35 Drugs Sorted by Highest Change to Government Cost, 2018-19 and 2019-20 (excl. under co-pay prescriptions)	11
Table 9(b)	Top 35 Drugs Sorted by Highest Change to Subsidised Script Volume, 2018-19 and 2019-20 (excl. under co-pay prescription)	12
Table 10(a)	PBS Section 85 Prescription Volume, 2016-17 to 2019-20 (incl. under co-pay prescriptions, Section 85 only)	13

Table 10(b)	PBS Section 85 expenditure, 2016-17 to 2019-20 (excl. under co-pay prescriptions, Section 85 only)	13
Table 11	PBS Prescriptions and Government Cost by Formulary, 2019-20 (incl. under co-pay prescriptions)	14
Table 12(a)	Top 20 Responsible Persons by Total Cost, 2019-20 (incl. under co-pay prescriptions)	15
Table 12(b)	Top 20 Responsible Persons by PBS Subsidised Prescriptions, 2019-20 (incl. under co-pay prescriptions)	16
Table 12(c)	Top 20 Responsible Persons by Total PBS Prescriptions, 2019-20 (incl. under co-pay prescriptions)	17
Table 13	Number of PBS Approved Suppliers, 30 June 2020	18
Table 14	PBS Brand Premiums, 2019-20	18
Table 15(a)	PBS/RPBS prescriptions dispensed by Community Pharmacies, 2019-20	19
Table 15(b)	PBS/RPBS prescriptions by Discount Range dispensed by Community Pharmacies, 2019-20	19
Table 16(a)	PBS/RPBS Medicines Supplied under Continued Dispensing (ongoing measure only) by Dispensing Pharmacy State, 2019-20	20
Table 16(b)	PBS/RPBS Continued Dispensing (ongoing measure only) Medicines Government Cost by Dispensing Pharmacy State, 2019-20	20
Table 16(c)	PBS/RPBS Medicines Supplied under Continued Dispensing (both Ongoing and Emergency Measures) by ATC Level 1 and Dispensing Pharmacy State, 2019-20	21
Table 16(d)	PBS/RPBS Continued Dispensing (both Ongoing and Emergency Measures) Government Cost by ATC Level 1 and Dispensing Pharmacy State, 2019-20	21
Supplement 1	Community Pharmacy Agreement (CPA) Expenses	
Table 17	Remuneration for Community Pharmacies and Friendly Societies, 2019-20 (excl. under co-pay prescriptions)	22
Table 18	CPA Professional Pharmacy Programs Expenditure, 2019-20	23
Table 19	Actual Costs of Major Components of CPA, 2019-20	24
Table 20	Community Services Obligation (CSO) Expenditure, 2019-20	24
Supplement 2	PBS Information Line Report, 2019-20	25
Supplement 3	National Diabetes Services Scheme (NDSS)	26
Supplement 4	Historical PBS Prescriptions and Expenditure	
Table 21(a)	Historical Pharmaceutical Benefits Scheme Prescriptions (1948-49 to 2019-20)	28
Table 21(b)	Historical Pharmaceutical Benefits Scheme Expenditure (1948-49 to 2019-20)	30

Table 1(a): PBS Expense on an Accrual Accounting Basis, 2018-19 and 2019-20

Category	2018-19	Percentage of Total	2019-20	Percentage of Total	Change	Change Percentage
Section 85 - Concessional	\$ 6,005,546,698	50.8%	\$ 6,433,841,718	51.0%	\$ 428,295,020	7.1%
Section 85 - General	\$ 1,951,411,697	16.5%	\$ 2,262,546,970	17.9%	\$ 311,135,273	15.9%
Doctors' Bag	\$ 17,598,747	0.1%	\$ 18,745,817	0.1%	\$ 1,147,070	6.5%
Section 100*	\$ 3,833,574,825	32.4%	\$ 3,886,499,581	30.8%	\$ 52,924,755	1.4%
Safety Net Cards	\$ 9,841,281	0.1%	\$ 12,070,996	0.1%	\$ 2,229,715	22.7%
Total	\$ 11,817,973,249	100.0%	\$ 12,613,705,082	100.0%	\$ 795,731,833	6.7%
Total Including Revenue**	\$ 9,576,017,986		\$ 9,828,680,554		\$ 252,662,568	2.6%

*Individual S100 programs are shown in Table 1(b).

**The basis for reporting PBS revenue has changed between 2015-16 and 2016-17, and this means that Total Including Revenue cannot be compared between 2015-16 and later years. The change in reporting PBS Revenue in 2016-17 brings this report into line with PBS revenue as reported in the Department of Health Annual Report.

Table 1(b): PBS Section 100 Programs on an Accrual Accounting Basis, 2018-19 and 2019-20

Category	2018-19	Percentage of Total	2019-20	Percentage of Total	Change	Change Percentage
Highly Specialised Drugs	\$ 1,922,113,426	50.1%	\$ 1,964,880,851	50.6%	\$ 42,767,426	2.2%
Chemotherapy (EFC & CPAP)	\$ 1,611,224,630	42.0%	\$ 1,597,332,043	41.1%	-\$ 13,892,587	-0.9%
In Vitro Fertilisation	\$ 116,891,228	3.0%	\$ 115,483,460	3.0%	-\$ 1,407,768	-1.2%
Opiate Dependence Treatment Program	\$ 60,197,175	1.6%	\$ 70,649,486	1.8%	\$ 10,452,311	17.4%
Aboriginal Health Services (GST exclusive)	\$ 45,535,967	1.2%	\$ 51,321,189	1.3%	\$ 5,785,222	12.7%
Botulinum Toxin Program (incl. Dysport)	\$ 48,697,916	1.3%	\$ 54,336,889	1.4%	\$ 5,638,974	11.6%
Growth Hormone	\$ 28,545,885	0.7%	\$ 31,903,234	0.8%	\$ 3,357,348	11.8%
Paraplegic and Quadriplegic Program	\$ 209,931	0.0%	\$ 393,060	0.0%	\$ 183,129	87.2%
Continuing Medication Program	\$ 158,667	0.0%	\$ 199,369	0.0%	\$ 40,701	25.7%
Total	\$ 3,833,574,825	100.0%	\$ 3,886,499,581	100.0%	\$ 52,924,755	1.4%

Note:

Expense figures refer to payments made through the Services Australia and directly from the Department of Health Financial Journaling System.

This data reflects the current definitions of Section 100 programs as published on www.pbs.gov.au.

Table 2(a): PBS Prescriptions, 2018-19 and 2019-20

Section 85 and S100*, including Drs Bag and under co-payment prescriptions

Patient Category	2018-19		2019-20		PBS Prescriptions Change	PBS Prescriptions Change Percentage
	PBS Prescriptions	Percentage	PBS Prescriptions	Percentage		
Concessional Non-Safety Net	149,585,866	72.9%	149,707,622	71.8%	121,756	0.1%
Concessional Safety Net	37,611,544	18.3%	40,395,717	19.4%	2,784,173	7.4%
Total Concessional	187,197,410	91.3%	190,103,339	91.2%	2,905,929	1.6%
General Non-Safety Net	14,854,973	7.2%	15,346,254	7.4%	491,281	3.3%
General Safety Net	2,660,158	1.3%	2,601,256	1.2%	58,902	-2.2%
Total General	17,515,131	8.5%	17,947,510	8.6%	432,379	2.5%
Doctors Bag	402,971	0.2%	418,823	0.2%	15,852	3.9%
Total (Over Co-payment)	205,115,512	100.0%	208,469,672	100.0%	3,354,160	1.6%
Under Co-payment	93,930,931		96,374,185		2,443,254	2.6%

Table 2(b): PBS Government Cost, 2018-19 and 2019-20

Section 85 and S100*, including Drs Bag and excluding under co-payment prescriptions

Patient Category	2018-19		2019-20		Government Cost Change	Government Cost Change Percentage
	Government Cost	Percentage	Government Cost	Percentage		
Concessional Non-Safety Net	\$ 6,417,526,165	54.9%	\$ 6,746,033,057	53.9%	\$ 328,506,892	5.1%
Concessional Safety Net	\$ 1,359,406,171	11.6%	\$ 1,507,326,553	12.1%	\$ 147,920,381	10.9%
Total Concessional	\$ 7,776,932,336	66.5%	\$ 8,253,359,610	66.0%	\$ 476,427,274	6.1%
General Non-Safety Net	\$ 3,781,798,452	32.3%	\$ 4,108,934,114	32.9%	\$ 327,135,662	8.7%
General Safety Net	\$ 123,564,550	1.1%	\$ 127,949,219	1.0%	\$ 4,384,668	3.5%
Total General	\$ 3,905,363,002	33.4%	\$ 4,236,883,333	33.9%	\$ 331,520,330	8.5%
Doctors Bag	\$ 16,008,172	0.1%	\$ 16,858,042	0.1%	\$ 849,870	5.3%
Total (Over Co-payment)	\$ 11,698,303,510	100.0%	\$ 12,507,100,984	100.0%	\$ 808,797,474	6.9%

Table 2(c): RPBS and PBS Subsidised Prescriptions for DVA patients, 2018-19 and 2019-20

PBS Section 85 and S100* and RPBS items for DVA patients, excluding under co-payment prescriptions

Patient Category	2018-19		2019-20		Subsidised Prescriptions Change	Subsidised Prescriptions Change Percentage
	Subsidised Prescriptions	Percentage	Subsidised Prescriptions	Percentage		
Repatriation Non-Safety Net	6,350,288	75%	5,887,565	73%	-462,723	-7.3%
Repatriation Safety Net	2,153,798	25%	2,205,251	27%	51,453	2.4%
Total Repatriation	8,504,086	100%	8,092,816	100%	-411,270	-4.8%

Table 2(d): RPBS and PBS Government Cost for DVA patients, 2018-19 and 2019-20

Section 85 and S100* and RPBS items for DVA patients, excluding under co-payment prescriptions

Patient Category	2018-19		2019-20		Government Cost Change	Government Cost Change Percentage
	Government Cost	Percentage	Government Cost	Percentage		
Repatriation Non-Safety Net	\$ 241,333,653	77%	\$ 242,630,275	76%	\$ 1,296,622	0.5%
Repatriation Safety Net	\$ 70,868,285	23%	\$ 75,393,631	24%	\$ 4,525,346	6.4%
Total Repatriation	\$ 312,201,938	100%	\$ 318,023,906	100%	\$ 5,821,968	1.9%

* Excludes Section 100 prescriptions supplied through Remote Area Aboriginal Health Services.

Table 3(a): PBS Section 85 Subsidised Prescriptions, Government Cost, Patient Contribution and Average Price, 2019-20
Section 85 only, including Drs Bag, excluding under co-payment prescriptions

Patient Category		PBS Subsidised Prescriptions	Government Cost	Patient Contribution***	Total Cost*	Ave. Price**
2019-20	Concessional Non-Safety Net	148,326,789	\$ 4,918,980,015	\$ 942,085,948	\$ 5,861,065,963	\$ 39.51
	Concessional Safety Net	40,280,313	\$ 1,370,238,848	\$ -	\$ 1,370,238,848	\$ 34.02
	Total Concessional	188,607,102	\$ 6,289,218,863	\$ 942,085,948	\$ 7,231,304,811	\$ 38.34
	General Non-Safety Net	13,873,735	\$ 2,142,135,695	\$ 512,660,643	\$ 2,654,796,339	\$ 191.35
	General Safety Net	2,577,950	\$ 104,447,648	\$ 16,287,445	\$ 120,735,093	\$ 46.83
	Total General	16,451,685	\$ 2,246,583,343	\$ 528,948,088	\$ 2,775,531,432	\$ 168.71
	Total (excluding Drs Bag)	205,058,787	\$ 8,535,802,207	\$ 1,471,034,036	\$ 10,006,836,242	\$ 48.80
	Doctors Bag	418,823	\$ 16,858,042	\$ -	\$ 16,858,042	\$ 40.25
Total (including Drs Bag)	205,477,610	\$ 8,552,660,248	\$ 1,471,034,036	\$ 10,023,694,284	\$ 48.78	

* Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions.

** Average Price is Total Cost divided by PBS Subsidised Prescriptions.

*** The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

Table 3(b): PBS Subsidised Prescriptions, Government Cost, Patient Contribution and Average Price, 2019-20
Section 85 and Section 100, including Drs Bag, excluding under co-payment prescriptions

Patient Category		PBS Subsidised Prescriptions	Government Cost	Patient Contribution***	Total Cost*	Ave. Price**
2019-20	Concessional Non-Safety Net	149,707,622	\$ 6,746,033,057	\$ 948,374,091	\$ 7,694,407,148	\$ 51.40
	Concessional Safety Net	40,395,717	\$ 1,507,326,553	\$ -	\$ 1,507,326,553	\$ 37.31
	Total Concessional	190,103,339	\$ 8,253,359,610	\$ 948,374,091	\$ 9,201,733,701	\$ 48.40
	General Non-Safety Net	15,346,254	\$ 4,108,934,114	\$ 555,060,457	\$ 4,663,994,571	\$ 303.92
	General Safety Net	2,601,256	\$ 127,949,219	\$ 16,402,241	\$ 144,351,460	\$ 55.49
	Total General	17,947,510	\$ 4,236,883,333	\$ 571,462,699	\$ 4,808,346,031	\$ 267.91
	Total (excluding Drs Bag)	208,050,849	\$ 12,490,242,942	\$ 1,519,836,790	\$ 14,010,079,732	\$ 67.34
	Doctors Bag	418,823	\$ 16,858,042	\$ -	\$ 16,858,042	\$ 40.25
Total (including Drs Bag)	208,469,672	\$ 12,507,100,984	\$ 1,519,836,790	\$ 14,026,937,774	\$ 67.29	

* Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions.

** Average Price is Total Cost divided by PBS Subsidised Prescriptions.

*** The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

Table 3(c): PBS Prescriptions, Government Cost, Patient Contribution and Average Price by Month of Supply, 2018-19 and 2019-20
Section 85 and Section 100, excluding Drs Bag and including under co-payment prescriptions

Year	Month	PBS Subsidised Prescriptions	Under Co-Payment Prescriptions	Total Prescriptions	Government Cost	Patient Contribution (Subsidised Prescriptions only)***	Total Cost*	Ave. Price**
2018	Jul	17,270,414	8,041,945	25,312,359	\$ 985,164,470	\$ 126,664,237	\$ 1,111,828,707	\$ 64.38
	Aug	17,867,493	8,204,542	26,072,035	\$ 988,000,161	\$ 122,530,769	\$ 1,110,530,930	\$ 62.15
	Sep	16,557,823	7,565,101	24,122,924	\$ 915,791,628	\$ 107,282,744	\$ 1,023,074,372	\$ 61.79
	Oct	18,236,635	7,837,904	26,074,539	\$ 1,025,112,317	\$ 109,416,484	\$ 1,134,528,801	\$ 62.21
	Nov	18,232,816	7,549,996	25,782,812	\$ 1,034,981,545	\$ 102,816,498	\$ 1,137,798,043	\$ 62.40
	Dec	19,621,741	7,432,757	27,054,498	\$ 1,056,527,261	\$ 98,044,007	\$ 1,154,571,268	\$ 58.84
2019	Jan	15,091,688	7,593,927	22,685,615	\$ 898,090,972	\$ 130,776,590	\$ 1,028,867,562	\$ 68.17
	Feb	15,030,815	7,321,192	22,352,007	\$ 882,363,373	\$ 129,882,375	\$ 1,012,245,749	\$ 67.34
	Mar	16,420,727	8,067,254	24,487,981	\$ 961,778,128	\$ 141,672,325	\$ 1,103,450,453	\$ 67.20
	Apr	16,327,302	7,881,249	24,208,551	\$ 937,972,909	\$ 138,708,229	\$ 1,076,681,139	\$ 65.94
	May	17,788,954	8,413,315	26,202,269	\$ 1,053,407,647	\$ 147,165,467	\$ 1,200,573,114	\$ 67.49
	Jun	16,266,133	8,021,747	24,287,880	\$ 943,104,928	\$ 129,876,242	\$ 1,072,981,171	\$ 65.96
Total		204,712,541	93,930,929	298,643,470	\$ 11,682,295,339	\$ 1,484,835,968	\$ 13,167,131,306	\$ 64.32
2019	Jul	17,911,377	8,503,599	26,414,976	\$ 1,062,545,341	\$ 134,453,865	\$ 1,196,999,206	\$ 66.83
	Aug	17,751,701	8,456,911	26,208,612	\$ 1,034,531,044	\$ 126,008,028	\$ 1,160,539,072	\$ 65.38
	Sep	17,014,710	7,923,645	24,938,355	\$ 1,010,394,938	\$ 113,621,708	\$ 1,124,016,646	\$ 66.06
	Oct	18,303,634	8,156,708	26,460,342	\$ 1,089,671,098	\$ 111,611,566	\$ 1,201,282,663	\$ 65.63
	Nov	17,863,839	7,763,292	25,627,131	\$ 1,061,803,450	\$ 103,108,592	\$ 1,164,912,043	\$ 65.21
	Dec	19,943,455	7,856,378	27,799,833	\$ 1,134,029,155	\$ 101,741,500	\$ 1,235,770,655	\$ 61.96
2020	Jan	15,248,218	7,972,450	23,220,668	\$ 957,865,799	\$ 133,910,147	\$ 1,091,775,946	\$ 71.60
	Feb	15,568,136	7,992,426	23,560,562	\$ 949,937,294	\$ 136,564,151	\$ 1,086,501,445	\$ 69.79
	Mar	19,866,555	10,408,974	30,275,529	\$ 1,176,717,668	\$ 180,243,259	\$ 1,356,960,927	\$ 68.30
	Apr	15,430,378	6,664,858	22,095,236	\$ 950,656,800	\$ 126,591,563	\$ 1,077,248,364	\$ 69.81
	May	16,139,826	7,225,397	23,365,223	\$ 999,177,521	\$ 126,945,388	\$ 1,126,122,910	\$ 69.77
	Jun	17,009,020	7,449,540	24,458,560	\$ 1,062,912,833	\$ 125,037,021	\$ 1,187,949,855	\$ 69.84
Total		208,050,849	96,374,178	304,425,027	\$ 12,490,242,942	\$ 1,519,836,790	\$ 14,010,079,732	\$ 67.34

* Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions.

** Average Price is Total Cost divided by PBS Subsidised Prescriptions.

*** The patient contribution includes the cost to the patient for PBS subsidised prescriptions. The patient contribution reported in table 3(b) in the 2017-18 report included under co-payment prescriptions. The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

Table 4: PBS Subsidised Prescriptions by Pharmacy State, 2019-20

Section 85 and Section 100[^], excluding Drs Bag and excluding under co-payment prescriptions

PBS S85 subsidised prescriptions	NSW	VIC	QLD	SA	WA	TAS	NT	ACT	Australia
Concessional Non-Safety Net	47,997,199	37,037,108	30,684,964	12,621,531	13,601,925	4,296,191	547,959	1,539,912	148,326,789
Concessional Safety Net	14,112,490	9,680,421	8,178,724	3,346,626	3,322,441	1,177,411	63,389	398,811	40,280,313
General Non-Safety Net	4,566,479	3,272,065	2,874,002	903,858	1,512,691	308,784	131,817	304,039	13,873,735
General Safety Net	914,943	609,593	471,120	173,882	281,580	49,529	7,933	69,370	2,577,950
Total	67,591,111	50,599,187	42,208,810	17,045,897	18,718,637	5,831,915	751,098	2,312,132	205,058,787
PBS (S85 + S100) subsidised prescriptions	NSW	VIC	QLD	SA	WA	TAS	NT	ACT	Australia
Concessional Non-Safety Net	48,411,985	37,392,339	30,976,622	12,730,766	13,735,028	4,332,575	558,099	1,570,208	149,707,622
Concessional Safety Net	14,144,653	9,714,998	8,203,842	3,355,076	3,332,390	1,180,474	63,701	400,583	40,395,717
General Non-Safety Net	5,056,364	3,637,009	3,136,941	999,405	1,672,353	330,939	145,895	367,348	15,346,254
General Safety Net	919,327	618,805	476,825	174,840	283,872	49,741	7,987	69,859	2,601,256
Total	68,532,329	51,363,151	42,794,230	17,260,087	19,023,643	5,893,729	775,682	2,407,998	208,050,849
Government Cost (S85 only)	NSW	VIC	QLD	SA	WA	TAS	NT	ACT	Australia
Concessional Non-Safety Net	\$ 1,621,669,820	\$ 1,200,074,565	\$ 1,019,813,262	\$ 407,943,582	\$ 456,163,927	\$ 141,126,469	\$ 17,764,070	\$ 54,424,320	\$ 4,918,980,015
Concessional Safety Net	\$ 477,178,173	\$ 328,837,250	\$ 276,945,287	\$ 111,652,380	\$ 116,900,530	\$ 41,811,395	\$ 2,011,452	\$ 14,902,382	\$ 1,370,238,848
General Non-Safety Net	\$ 684,833,229	\$ 573,491,570	\$ 394,256,472	\$ 145,100,052	\$ 231,501,828	\$ 50,703,460	\$ 14,415,665	\$ 47,833,421	\$ 2,142,135,695
General Safety Net	\$ 36,249,584	\$ 25,322,054	\$ 18,157,595	\$ 6,875,206	\$ 12,521,637	\$ 2,133,974	\$ 273,858	\$ 2,913,741	\$ 104,447,648
Total	\$ 2,819,930,805	\$ 2,127,725,439	\$ 1,709,172,615	\$ 671,571,220	\$ 817,087,922	\$ 235,775,297	\$ 34,465,044	\$ 120,073,865	\$ 8,535,802,207
Government Cost (S85 + S100)	NSW	VIC	QLD	SA	WA	TAS	NT	ACT	Australia
Concessional Non-Safety Net	\$ 2,165,393,547	\$ 1,639,031,902	\$ 1,438,929,319	\$ 558,749,593	\$ 639,396,875	\$ 196,950,645	\$ 27,908,552	\$ 79,672,624	\$ 6,746,033,057
Concessional Safety Net	\$ 510,290,989	\$ 367,300,589	\$ 309,931,377	\$ 124,770,309	\$ 129,634,918	\$ 46,770,258	\$ 2,246,330	\$ 16,381,784	\$ 1,507,326,553
General Non-Safety Net	\$ 1,357,399,774	\$ 1,039,503,085	\$ 767,925,978	\$ 273,268,412	\$ 454,139,866	\$ 83,095,534	\$ 33,237,571	\$ 100,363,894	\$ 4,108,934,114
General Safety Net	\$ 41,188,185	\$ 32,914,271	\$ 24,015,877	\$ 8,343,209	\$ 15,330,540	\$ 2,393,951	\$ 323,423	\$ 3,439,762	\$ 127,949,219
Total	\$ 4,074,272,496	\$ 3,078,749,847	\$ 2,540,802,551	\$ 965,131,524	\$ 1,238,502,198	\$ 329,210,387	\$ 63,715,876	\$ 199,858,064	\$ 12,490,242,942
Total Cost (S85 + S100)*	NSW	VIC	QLD	SA	WA	TAS	NT	ACT	Australia
Concessional Non-Safety Net	\$ 2,470,113,217	\$ 1,881,382,471	\$ 1,632,624,209	\$ 639,830,500	\$ 725,758,341	\$ 224,230,392	\$ 30,701,028	\$ 89,766,992	\$ 7,694,407,148
Concessional Safety Net	\$ 510,290,989	\$ 367,300,589	\$ 309,931,377	\$ 124,770,309	\$ 129,634,918	\$ 46,770,258	\$ 2,246,330	\$ 16,381,784	\$ 1,507,326,553
General Non-Safety Net	\$ 1,536,797,053	\$ 1,180,271,135	\$ 876,160,719	\$ 309,604,206	\$ 514,825,224	\$ 94,637,034	\$ 37,195,117	\$ 114,504,083	\$ 4,663,994,571
General Safety Net	\$ 46,963,137	\$ 36,898,943	\$ 26,984,329	\$ 9,446,246	\$ 17,105,812	\$ 2,700,261	\$ 365,859	\$ 3,886,875	\$ 144,351,460
Total	\$ 4,564,164,396	\$ 3,465,853,138	\$ 2,845,700,634	\$ 1,083,651,261	\$ 1,387,324,294	\$ 368,337,943	\$ 70,508,333	\$ 224,539,733	\$ 14,010,079,732
Population Percentage	NSW	VIC	QLD	SA	WA	TAS	NT	ACT	Australia
Population**	8,130,159	6,655,284	5,133,278	1,759,783	2,642,120	537,907	244,989	427,892	25,536,073
PBS S85 Subsidised Scripts per Capita	8.31	7.60	8.22	9.69	7.08	10.84	3.07	5.40	8.03
PBS (S85 + S100) Subsidised Scripts per Capita	8.43	7.72	8.34	9.81	7.20	10.96	3.17	5.63	8.15
PBS S85 Govt Cost per Capita	\$ 346.85	\$ 319.70	\$ 332.96	\$ 381.62	\$ 309.25	\$ 438.32	\$ 140.68	\$ 280.62	\$ 334.26
PBS (S85 + S100) Govt Cost per Capita	\$ 501.13	\$ 462.60	\$ 494.97	\$ 548.44	\$ 468.75	\$ 612.02	\$ 260.08	\$ 467.08	\$ 489.12
Population Percentage	31.84%	26.06%	20.10%	6.89%	10.35%	2.11%	0.96%	1.68%	100.00%
PBS (S85 + S100) Subsidised Scripts Percentage	32.94%	24.69%	20.57%	8.30%	9.14%	2.83%	0.37%	1.16%	100.00%
PBS (S85 + S100) Govt Cost Percentage	32.62%	24.65%	20.34%	7.73%	9.92%	2.64%	0.51%	1.60%	100.00%
Total Cost Percentage	32.58%	24.74%	20.31%	7.73%	9.90%	2.63%	0.50%	1.60%	100.00%

* Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions (S85 + S100 prescriptions).

**Population 31 December 2019, Source: ABS Publication 3101.04

[^] Excludes Section 100 prescriptions supplied through Remote Area Aboriginal Health Services.

Table 5(a): Top 50 PBS Drugs (by Active Ingredient) Sorted by Highest Government Cost, 2019-20
 Section 85 and Section 100[^], including Drs Bag, excluding under co-payment prescriptions

Rank	Drug Name	PBS Subsidised Prescriptions	Government Cost	Patient Contribution***	Total Cost*	Ave. Price**
1	AFLIBERCEPT	299,955	\$ 372,844,440	\$ 4,562,127	\$ 377,406,567	\$ 1,258.21
2	NIVOLUMAB	50,323	\$ 333,970,002	\$ 236,244	\$ 334,206,247	\$ 6,641.22
3	PEMBROLIZUMAB	37,568	\$ 331,481,924	\$ 166,331	\$ 331,648,255	\$ 8,827.95
4	ADALIMUMAB	255,529	\$ 318,747,705	\$ 7,179,217	\$ 325,926,922	\$ 1,275.50
5	DENOSUMAB	857,062	\$ 236,822,977	\$ 10,260,220	\$ 247,083,197	\$ 288.29
6	SOFOSBUVIR + VELPATASVIR	17,716	\$ 223,269,539	\$ 377,375	\$ 223,646,915	\$ 12,624.01
7	USTEKINUMAB	29,392	\$ 209,733,381	\$ 885,599	\$ 210,618,980	\$ 7,165.86
8	RANIBIZUMAB	178,604	\$ 204,683,547	\$ 2,407,211	\$ 207,090,758	\$ 1,159.50
9	APIXABAN	2,480,138	\$ 201,261,551	\$ 29,244,594	\$ 230,506,145	\$ 92.94
10	GLECAPREVIR + PIBRENTASVIR	9,945	\$ 186,524,509	\$ 246,061	\$ 186,770,570	\$ 18,780.35
11	LENALIDOMIDE	28,133	\$ 165,780,317	\$ 457,077	\$ 166,237,394	\$ 5,908.98
12	LUMACAFTOR + IVACAFTOR	8,607	\$ 159,493,461	\$ 117,799	\$ 159,611,261	\$ 18,544.35
13	RIVAROXABAN	2,083,921	\$ 149,937,278	\$ 29,241,833	\$ 179,179,110	\$ 85.98
14	IBRUTINIB	15,479	\$ 142,932,301	\$ 223,581	\$ 143,155,882	\$ 9,248.39
15	OCRELIZUMAB	8,133	\$ 140,315,361	\$ 261,442	\$ 140,576,803	\$ 17,284.74
16	FINGOLIMOD	57,445	\$ 125,378,702	\$ 1,591,821	\$ 126,970,523	\$ 2,210.30
17	TRASTUZUMAB	63,243	\$ 115,979,979	\$ 753,604	\$ 116,733,583	\$ 1,845.79
18	ENZALUTAMIDE	29,278	\$ 106,842,963	\$ 345,903	\$ 107,188,866	\$ 3,661.07
19	ETANERCEPT	102,999	\$ 105,496,059	\$ 2,412,811	\$ 107,908,870	\$ 1,047.67
20	IPILIMUMAB	3,894	\$ 96,066,573	\$ 41,852	\$ 96,108,426	\$ 24,681.16
21	INFLIXIMAB	61,416	\$ 95,059,522	\$ 2,039,622	\$ 97,099,143	\$ 1,581.01
22	ROSUVASTATIN	7,800,628	\$ 94,490,269	\$ 41,712,052	\$ 136,202,321	\$ 17.46
23	FLUTICASON PROPRIONATE + SALMETEROL	2,342,135	\$ 90,378,751	\$ 42,900,666	\$ 133,279,417	\$ 56.91
24	FERRIC CARBOXYMALTOSE	334,860	\$ 90,341,109	\$ 8,576,163	\$ 98,917,272	\$ 295.40
25	PREGABALIN	3,251,002	\$ 87,016,603	\$ 18,672,874	\$ 105,689,477	\$ 32.51
26	BEVACIZUMAB	41,613	\$ 86,883,069	\$ 204,040	\$ 87,087,109	\$ 2,092.79
27	RITUXIMAB	40,610	\$ 85,321,014	\$ 351,191	\$ 85,672,205	\$ 2,109.63
28	GOLIMUMAB	64,935	\$ 83,065,828	\$ 1,752,368	\$ 84,818,195	\$ 1,306.20
29	PEGFILGRASTIM	69,801	\$ 81,999,903	\$ 1,990,319	\$ 83,990,222	\$ 1,203.28
30	INSULIN GLARGINE	384,314	\$ 79,900,208	\$ 5,702,871	\$ 85,603,079	\$ 222.74
31	TOFACITINIB	62,002	\$ 77,281,677	\$ 1,293,622	\$ 78,575,299	\$ 1,267.30
32	ESOMEPRAZOLE	5,605,278	\$ 76,804,956	\$ 28,373,600	\$ 105,178,556	\$ 18.76
33	BICTEGRAVIR + EMTRICITABINE + TENOFOVIR ALAFENAMIDE	41,963	\$ 74,147,901	\$ 1,245,984	\$ 75,393,885	\$ 1,796.68
34	PALIPERIDONE	225,296	\$ 73,848,240	\$ 2,374,431	\$ 76,222,670	\$ 338.32
35	RIBOCICLIB	15,180	\$ 72,596,948	\$ 308,738	\$ 72,905,686	\$ 4,802.75
36	SECUKINUMAB	51,909	\$ 72,228,339	\$ 1,454,791	\$ 73,683,130	\$ 1,419.47
37	DARBEPOETIN ALFA	67,104	\$ 69,549,965	\$ 942,446	\$ 70,492,411	\$ 1,050.49
38	VEDOLIZUMAB	22,243	\$ 68,869,316	\$ 721,418	\$ 69,590,734	\$ 3,128.66
39	CLADRIBINE	4,264	\$ 68,743,467	\$ 101,918	\$ 68,845,385	\$ 16,145.73
40	ATORVASTATIN	7,540,302	\$ 68,410,099	\$ 39,223,649	\$ 107,633,748	\$ 14.27
41	BUDESONIDE + FORMOTEROL (EFORMOTEROL)	2,002,220	\$ 67,854,969	\$ 40,297,136	\$ 108,152,105	\$ 54.02
42	IVACAFTOR	3,017	\$ 67,298,794	\$ 51,516	\$ 67,350,310	\$ 22,323.60
43	OXYCODONE + NALOXONE	1,637,230	\$ 63,662,390	\$ 11,549,220	\$ 75,211,611	\$ 45.94
44	LEVODOPA + CARBIDOPA	266,088	\$ 63,072,085	\$ 1,735,575	\$ 64,807,660	\$ 243.56
45	RUXOLITINIB	12,824	\$ 62,997,967	\$ 202,469	\$ 63,200,437	\$ 4,928.29
46	SACUBITRIL + VALSARTAN	336,934	\$ 62,355,840	\$ 4,494,350	\$ 66,850,191	\$ 198.41
47	ARIPIPRAZOLE	359,376	\$ 62,066,030	\$ 4,596,006	\$ 66,662,036	\$ 185.49
48	ATEZOLIZUMAB	8,232	\$ 61,979,194	\$ 49,557	\$ 62,028,751	\$ 7,535.08
49	GOSERELIN	108,131	\$ 59,790,130	\$ 2,414,991	\$ 62,205,121	\$ 575.28
50	BORTEZOMIB	43,582	\$ 58,507,083	\$ 96,699	\$ 58,603,782	\$ 1,344.68

* Total Cost includes cost to the patient and cost to the Government for PBS (\$85 + \$100) subsidised prescriptions.

** Average Price is Total Cost divided by PBS Subsidised Prescriptions.

*** The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

[^] Excludes Section 100 prescriptions supplied through Remote Area Aboriginal Health Services.

Table 5(b): Top 50 PBS Drugs (by Active Ingredient) Sorted by Highest Subsidised Prescriptions, 2019-20
 Section 85 and Section 100[^], including Drs Bag, excluding under co-payment prescriptions

Rank	Drug Name	PBS Subsidised Prescriptions	Government Cost	Patient Contribution***	Total Cost*	Ave. Price**
1	ROSUVASTATIN	7,800,628	\$ 94,490,269	\$ 41,712,052	\$ 136,202,321	\$ 17.46
2	ATORVASTATIN	7,540,302	\$ 68,410,099	\$ 39,223,649	\$ 107,633,748	\$ 14.27
3	PANTOPRAZOLE	5,691,237	\$ 50,476,431	\$ 28,530,358	\$ 79,006,789	\$ 13.88
4	ESOMEPRAZOLE	5,605,278	\$ 76,804,956	\$ 28,373,600	\$ 105,178,556	\$ 18.76
5	PERINDOPRIL	3,980,870	\$ 36,725,938	\$ 21,316,927	\$ 58,042,866	\$ 14.58
6	METFORMIN	3,299,533	\$ 35,159,985	\$ 15,793,979	\$ 50,953,965	\$ 15.44
7	PREGABALIN	3,251,002	\$ 87,016,603	\$ 18,672,874	\$ 105,689,477	\$ 32.51
8	SALBUTAMOL	3,058,953	\$ 47,570,183	\$ 13,391,906	\$ 60,962,089	\$ 19.93
9	AMLODIPINE	2,675,707	\$ 19,882,634	\$ 13,896,241	\$ 33,778,875	\$ 12.62
10	IRBESARTAN	2,660,990	\$ 22,994,624	\$ 14,148,519	\$ 37,143,143	\$ 13.96
11	CEFALEXIN	2,551,840	\$ 21,729,025	\$ 13,633,895	\$ 35,362,920	\$ 13.86
12	APIXABAN	2,480,138	\$ 201,261,551	\$ 29,244,594	\$ 230,506,145	\$ 92.94
13	FLUTICASONE PROPIONATE + SALMETEROL	2,342,135	\$ 90,378,751	\$ 42,900,666	\$ 133,279,417	\$ 56.91
14	TELMISARTAN	2,247,646	\$ 20,727,677	\$ 12,325,092	\$ 33,052,770	\$ 14.71
15	PARACETAMOL + CODEINE	2,225,831	\$ 28,451,811	\$ 11,067,113	\$ 39,518,924	\$ 17.75
16	CANDESARTAN	2,174,232	\$ 19,471,656	\$ 11,739,904	\$ 31,211,560	\$ 14.36
17	ATENOLOL	2,160,813	\$ 17,229,899	\$ 11,095,513	\$ 28,325,412	\$ 13.11
18	SERTRALINE	2,153,769	\$ 18,035,423	\$ 11,668,604	\$ 29,704,027	\$ 13.79
19	ESCITALOPRAM	2,089,633	\$ 17,932,521	\$ 11,520,696	\$ 29,453,216	\$ 14.09
20	RIVAROXABAN	2,083,921	\$ 149,937,278	\$ 29,241,833	\$ 179,179,110	\$ 85.98
21	RAMIPRIL	2,083,339	\$ 17,829,204	\$ 10,816,961	\$ 28,646,166	\$ 13.75
22	MIRTAZAPINE	2,037,113	\$ 21,798,288	\$ 10,124,217	\$ 31,922,505	\$ 15.67
23	OXYCODONE	2,013,526	\$ 44,755,263	\$ 11,121,872	\$ 55,877,135	\$ 27.75
24	BUDESONIDE + FORMOTEROL (EFORMOTEROL)	2,002,220	\$ 67,854,969	\$ 40,297,136	\$ 108,152,105	\$ 54.02
25	AMOXICILLIN	1,858,417	\$ 15,836,264	\$ 10,361,056	\$ 26,197,320	\$ 14.10
26	SIMVASTATIN	1,811,503	\$ 15,079,647	\$ 9,346,045	\$ 24,425,692	\$ 13.48
27	AMOXICILLIN + CLAVULANIC ACID	1,796,198	\$ 16,848,811	\$ 9,556,863	\$ 26,405,674	\$ 14.70
28	CLOPIDOGREL	1,785,652	\$ 19,291,252	\$ 8,418,182	\$ 27,709,434	\$ 15.52
29	METOPROLOL TARTRATE	1,782,526	\$ 15,231,934	\$ 8,668,113	\$ 23,900,047	\$ 13.41
30	VENLAFAXINE	1,739,256	\$ 19,560,135	\$ 9,244,737	\$ 28,804,872	\$ 16.56
31	TRAMADOL	1,712,955	\$ 22,559,836	\$ 7,931,715	\$ 30,491,551	\$ 17.80
32	RABEPRAZOLE	1,708,068	\$ 16,295,184	\$ 8,703,847	\$ 24,999,031	\$ 14.64
33	LERCANIDIPINE	1,639,149	\$ 15,199,644	\$ 8,278,579	\$ 23,478,223	\$ 14.32
34	OXYCODONE + NALOXONE	1,637,230	\$ 63,662,390	\$ 11,549,220	\$ 75,211,611	\$ 45.94
35	AMITRIPTYLINE	1,625,160	\$ 15,717,950	\$ 7,882,639	\$ 23,600,589	\$ 14.52
36	DIAZEPAM	1,606,984	\$ 12,139,904	\$ 8,088,973	\$ 20,228,877	\$ 12.59
37	PARACETAMOL	1,558,845	\$ 21,924,905	\$ 6,118,415	\$ 28,043,320	\$ 17.99
38	SITAGLIPTIN + METFORMIN	1,497,917	\$ 56,869,478	\$ 25,382,602	\$ 82,252,080	\$ 54.91
39	IRBESARTAN + HYDROCHLOROTHIAZIDE	1,488,737	\$ 14,315,562	\$ 8,023,546	\$ 22,339,107	\$ 15.01
40	TIOTROPIUM	1,488,248	\$ 58,220,571	\$ 14,041,895	\$ 72,262,466	\$ 48.56
41	FUROSEMIDE (FRUSEMIDE)	1,472,612	\$ 13,014,765	\$ 6,437,089	\$ 19,451,854	\$ 13.21
42	PERINDOPRIL + AMLODIPINE	1,441,268	\$ 15,704,898	\$ 8,111,688	\$ 23,816,586	\$ 16.52
43	OMEPRAZOLE	1,392,747	\$ 15,313,985	\$ 7,074,903	\$ 22,388,888	\$ 16.08
44	GLICLAZIDE	1,341,712	\$ 18,695,306	\$ 6,055,567	\$ 24,750,873	\$ 18.45
45	MELOXICAM	1,325,893	\$ 13,174,281	\$ 6,888,669	\$ 20,062,950	\$ 15.13
46	BISOPROLOL	1,318,636	\$ 19,796,564	\$ 6,459,424	\$ 26,255,988	\$ 19.91
47	PREDNISOLONE	1,315,955	\$ 12,639,462	\$ 6,438,371	\$ 19,077,832	\$ 14.50
48	MACROGOL-3350 + SODIUM CHLORIDE + BICARBONATE + POTASSIUM CHLORIDE	1,264,937	\$ 19,220,064	\$ 5,612,347	\$ 24,832,410	\$ 19.63
49	TEMAZEPAM	1,217,551	\$ 9,420,841	\$ 5,821,140	\$ 15,241,981	\$ 12.52
50	DUTASTERIDE + TAMSULOSIN	1,215,817	\$ 33,040,388	\$ 6,086,308	\$ 39,126,696	\$ 32.18

* Total Cost includes cost to the patient and cost to the Government for PBS (S85 + S100) subsidised prescriptions.

** Average Price is Total Cost divided by PBS Subsidised Prescriptions.

*** The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

[^] Excludes Section 100 prescriptions supplied through Remote Area Aboriginal Health Services.

Table 5(c): Top 25 PBS Cancer Drugs[^] (by Active Ingredient) Sorted by Highest Government Cost, 2019-20

Section 85 and Section 100^{^^}, excluding under co-payment prescriptions, including Drs Bag

Rank	Drug Name	PBS Subsidised Prescriptions	Government Cost	Patient Contribution***	Total Cost*	Ave. Price**
1	NIVOLUMAB	50,323	\$ 333,970,002	\$ 236,244	\$ 334,206,247	\$ 6,641.22
2	PEMBROLIZUMAB	37,568	\$ 331,481,924	\$ 166,331	\$ 331,648,255	\$ 8,827.95
3	LENALIDOMIDE	28,133	\$ 165,780,317	\$ 457,077	\$ 166,237,394	\$ 5,908.98
4	IBRUTINIB	15,479	\$ 142,932,301	\$ 223,581	\$ 143,155,882	\$ 9,248.39
5	TRASTUZUMAB	63,243	\$ 115,979,979	\$ 753,604	\$ 116,733,583	\$ 1,845.79
6	ENZALUTAMIDE	29,278	\$ 106,842,963	\$ 345,903	\$ 107,188,866	\$ 3,661.07
7	IPILIMUMAB	3,894	\$ 96,066,573	\$ 41,852	\$ 96,108,426	\$ 24,681.16
8	BEVACIZUMAB	41,613	\$ 86,883,069	\$ 204,040	\$ 87,087,109	\$ 2,092.79
9	RITUXIMAB ^{^^^}	36,530	\$ 74,650,360	\$ 254,535	\$ 74,904,895	\$ 2,050.50
10	RIBOCICLIB	15,180	\$ 72,596,948	\$ 308,738	\$ 72,905,686	\$ 4,802.75
11	RUXOLITINIB	12,824	\$ 62,997,967	\$ 202,469	\$ 63,200,437	\$ 4,928.29
12	ATEZOLIZUMAB	8,232	\$ 61,979,194	\$ 49,557	\$ 62,028,751	\$ 7,535.08
13	GOSERELIN ^{^^^^}	108,131	\$ 59,790,130	\$ 2,414,991	\$ 62,205,121	\$ 575.28
14	BORTEZOMIB	43,582	\$ 58,507,083	\$ 96,699	\$ 58,603,782	\$ 1,344.68
15	PERTUZUMAB	17,466	\$ 57,517,417	\$ 133,270	\$ 57,650,687	\$ 3,300.74
16	DASATINIB	12,531	\$ 54,009,833	\$ 331,798	\$ 54,341,631	\$ 4,336.58
17	CARFILZOMIB	23,012	\$ 52,780,181	\$ 35,220	\$ 52,815,400	\$ 2,295.12
18	ABIRATERONE	15,291	\$ 52,358,639	\$ 176,778	\$ 52,535,417	\$ 3,435.71
19	TRAMETINIB	6,180	\$ 50,082,550	\$ 130,992	\$ 50,213,543	\$ 8,125.17
20	PALBOCICLIB	11,319	\$ 47,717,548	\$ 239,731	\$ 47,957,278	\$ 4,236.88
21	LEUPRORELIN ^{^^^}	45,713	\$ 47,152,778	\$ 593,508	\$ 47,746,286	\$ 1,044.48
22	DABRAFENIB	6,046	\$ 46,345,973	\$ 128,192	\$ 46,474,165	\$ 7,686.76
23	OBINUTUZUMAB	7,661	\$ 41,788,505	\$ 31,277	\$ 41,819,782	\$ 5,458.79
24	POMALIDOMIDE	3,541	\$ 37,062,373	\$ 52,269	\$ 37,114,642	\$ 10,481.40
25	IMATINIB	27,298	\$ 36,903,321	\$ 564,449	\$ 37,467,770	\$ 1,372.55

* Total Cost includes cost to the patient and cost to the Government for PBS (S85 + S100) subsidised prescriptions.

** Average Price is Total Cost divided by PBS Subsidised Prescriptions.

*** The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

[^] Excludes cancer supportive drugs.

^{^^} Excludes Section 100 prescriptions supplied through Remote Area Aboriginal Health Services.

^{^^^} Excludes PBS items that are not for cancer treatment.

^{^^^^} Some of the usage may be for treating other conditions.

Table 5(d): Top 25 PBS Biological Drugs (by Active Ingredient) Sorted by Highest Government Cost, 2019-20

Section 85 and Section 100[^], excluding under co-payment prescriptions, including Drs Bag

Rank	Drug Name	PBS Subsidised Prescriptions	Government Cost	Patient Contribution***	Total Cost*	Ave. Price**
1	AFLIBERCEPT	299,955	\$ 372,844,440	\$ 4,562,127	\$ 377,406,567	\$ 1,258.21
2	NIVOLUMAB	50,323	\$ 333,970,002	\$ 236,244	\$ 334,206,247	\$ 6,641.22
3	PEMBROLIZUMAB	37,568	\$ 331,481,924	\$ 166,331	\$ 331,648,255	\$ 8,827.95
4	ADALIMUMAB	255,529	\$ 318,747,705	\$ 7,179,217	\$ 325,926,922	\$ 1,275.50
5	DENOSUMAB	857,062	\$ 236,822,977	\$ 10,260,220	\$ 247,083,197	\$ 288.29
6	USTEKINUMAB	29,392	\$ 209,733,381	\$ 885,599	\$ 210,618,980	\$ 7,165.86
7	RANIBIZUMAB	178,604	\$ 204,683,547	\$ 2,407,211	\$ 207,090,758	\$ 1,159.50
8	OCRELIZUMAB	8,133	\$ 140,315,361	\$ 261,442	\$ 140,576,803	\$ 17,284.74
9	TRASTUZUMAB	63,243	\$ 115,979,979	\$ 753,604	\$ 116,733,583	\$ 1,845.79
10	ETANERCEPT	102,999	\$ 105,496,059	\$ 2,412,811	\$ 107,908,870	\$ 1,047.67
11	IPILIMUMAB	3,894	\$ 96,066,573	\$ 41,852	\$ 96,108,426	\$ 24,681.16
12	INFLIXIMAB	61,416	\$ 95,059,522	\$ 2,039,622	\$ 97,099,143	\$ 1,581.01
13	BEVACIZUMAB	41,613	\$ 86,883,069	\$ 204,040	\$ 87,087,109	\$ 2,092.79
14	RITUXIMAB	40,610	\$ 85,321,014	\$ 351,191	\$ 85,672,205	\$ 2,109.63
15	GOLIMUMAB	64,935	\$ 83,065,828	\$ 1,752,368	\$ 84,818,195	\$ 1,306.20
16	PEGFILGRASTIM	69,801	\$ 81,999,903	\$ 1,990,319	\$ 83,990,222	\$ 1,203.28
17	INSULIN GLARGINE	384,314	\$ 79,900,208	\$ 5,702,872	\$ 85,603,079	\$ 222.74
18	SECUKINUMAB	51,909	\$ 72,228,339	\$ 1,454,791	\$ 73,683,130	\$ 1,419.47
19	DARBEPOETIN ALFA	67,104	\$ 69,549,965	\$ 942,446	\$ 70,492,411	\$ 1,050.49
20	VEDOLIZUMAB	22,243	\$ 68,869,316	\$ 721,418	\$ 69,590,734	\$ 3,128.66
21	ATEZOLIZUMAB	8,232	\$ 61,979,194	\$ 49,557	\$ 62,028,751	\$ 7,535.08
22	PERTUZUMAB	17,466	\$ 57,517,417	\$ 133,270	\$ 57,650,687	\$ 3,300.74
23	INSULIN ASPART	305,457	\$ 54,064,687	\$ 6,170,925	\$ 60,235,612	\$ 197.20
24	FOLLITROPIN ALFA	40,401	\$ 47,223,913	\$ 1,561,101	\$ 48,785,014	\$ 1,207.52
25	ECULIZUMAB	984	\$ 45,574,435	\$ 27,768	\$ 45,602,203	\$ 46,343.70

* Total Cost includes cost to the patient and cost to the Government for PBS (S85 + S100) subsidised prescriptions.

** Average Price is Total Cost divided by PBS Subsidised Prescriptions.

*** The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

[^] Excludes Section 100 prescriptions supplied through Remote Area Aboriginal Health Services.

Table 6: Top 50 PBS Drugs (by Active Ingredient) Sorted by Highest Total Prescription Volume, 2019-20
 Section 85 and Section 100[^], including Drs Bag and under co-payment prescriptions

Rank	Drug Name	PBS Subsidised Prescriptions	Under Co-Payment Prescriptions	Total Prescription Volume	Total Government Cost
1	ROSUVASTATIN	7,800,628	4,933,116	12,733,744	\$ 136,202,321
2	ATORVASTATIN	7,540,302	3,463,604	11,003,906	\$ 107,633,748
3	PANTOPRAZOLE	5,691,237	2,377,349	8,068,586	\$ 79,006,789
4	ESOMEPRAZOLE	5,605,278	2,347,910	7,953,188	\$ 105,178,556
5	PERINDOPRIL	3,980,870	2,576,511	6,557,381	\$ 58,042,866
6	CEFALEXIN	2,551,840	2,702,321	5,254,161	\$ 35,362,920
7	METFORMIN	3,299,533	1,802,582	5,102,115	\$ 50,953,965
8	ESCITALOPRAM	2,089,633	2,811,465	4,901,098	\$ 29,453,216
9	AMOXICILLIN	1,858,417	2,887,528	4,745,945	\$ 26,197,320
10	SERTRALINE	2,153,769	2,491,817	4,645,586	\$ 29,704,027
11	AMOXICILLIN + CLAVULANIC ACID	1,796,198	2,269,177	4,065,375	\$ 26,405,674
12	IRBESARTAN	2,660,990	1,344,490	4,005,480	\$ 37,143,143
13	SALBUTAMOL	3,058,953	933,416	3,992,369	\$ 60,962,089
14	PREGABALIN	3,251,002	711,364	3,962,366	\$ 105,689,477
15	AMLODIPINE	2,675,707	1,255,505	3,931,212	\$ 33,778,875
16	TELMISARTAN	2,247,646	1,625,788	3,873,434	\$ 33,052,770
17	PARACETAMOL + CODEINE	2,226,831	1,540,579	3,767,410	\$ 39,518,924
18	CANDESARTAN	2,174,232	1,334,009	3,508,241	\$ 31,211,560
19	RAMIPRIL	2,083,339	1,174,950	3,258,289	\$ 28,646,166
20	VENLAFAXINE	1,739,256	1,454,277	3,193,533	\$ 28,804,872
21	OXYCODONE	2,013,526	1,068,954	3,082,480	\$ 55,877,135
22	ATENOLOL	2,160,813	870,969	3,031,782	\$ 28,325,412
23	MIRTAZAPINE	2,037,113	774,441	2,811,554	\$ 31,922,505
24	PERINDOPRIL + AMLODIPINE	1,441,268	1,210,044	2,651,312	\$ 23,816,586
25	RABEPRAZOLE	1,708,068	822,182	2,530,250	\$ 24,999,031
26	AMITRIPTYLINE	1,625,160	889,031	2,514,191	\$ 23,600,589
27	APIXABAN	2,480,138	646	2,480,784	\$ 230,506,145
28	TRAMADOL	1,712,955	761,362	2,474,317	\$ 30,491,551
29	DIAZEPAM	1,606,984	825,609	2,432,593	\$ 20,228,877
30	MELOXICAM	1,325,893	1,079,218	2,405,111	\$ 20,062,950
31	PREDNISOLONE	1,315,955	1,069,470	2,385,425	\$ 19,077,832
32	METOPROLOL TARTRATE	1,782,526	587,004	2,369,530	\$ 23,900,047
33	FLUTICASONE PROPIONATE + SALMETEROL	2,342,135	429	2,342,564	\$ 133,279,417
34	DOXYCYCLINE	1,095,053	1,237,743	2,332,796	\$ 15,182,831
35	SIMVASTATIN	1,811,503	511,503	2,323,006	\$ 24,425,692
36	DESVENLAFAXINE	1,171,599	1,110,349	2,281,948	\$ 31,072,104
37	FLUOXETINE	1,045,509	1,205,027	2,250,536	\$ 19,242,242
38	IRBESARTAN + HYDROCHLOROTHIAZIDE	1,488,737	737,019	2,225,756	\$ 22,339,107
39	CLOPIDOGREL	1,785,652	429,847	2,215,499	\$ 27,709,434
40	LERCANIDIPINE	1,639,149	570,482	2,209,631	\$ 23,478,223
41	RIVAROXABAN	2,083,921	1,302	2,085,223	\$ 179,179,110
42	BUDESONIDE + FORMOTEROL (EFORMOTEROL)	2,002,220	11,735	2,013,955	\$ 108,152,105
43	OMEPRAZOLE	1,392,747	556,016	1,948,763	\$ 22,388,888
44	OXYCODONE + NALOXONE	1,637,230	285,348	1,922,578	\$ 75,211,611
45	DULOXETINE	1,102,516	776,471	1,878,987	\$ 20,461,988
46	LEVOTHYROXINE	1,032,553	842,088	1,874,641	\$ 27,289,332
47	LEVONORGESTREL + ETHINYLESTRADIOL	370,885	1,471,046	1,841,931	\$ 6,613,112
48	GLICLAZIDE	1,341,712	474,866	1,816,578	\$ 24,750,873
49	BISOPROLOL	1,318,636	437,906	1,756,542	\$ 26,255,988
50	CITALOPRAM	963,621	789,006	1,752,627	\$ 12,831,903

[^] Excludes Section 100 prescriptions supplied through Remote Area Aboriginal Health Services.

Table 7: Top 50 ATC Level 2 Drug Groups Sorted by Highest Total Prescription Volume, 2019-20
 Section 85 and Section 100[^], including Drs Bag and under co-payment prescriptions

Rank	ATC Level 2 Code	ATC Level 2 Group	PBS Subsidised Prescriptions	Under Co-Payment Prescriptions	Total Prescriptions
1	C09	AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM	23,375,867	14,691,330	38,067,197
2	C10	LIPID MODIFYING AGENTS	21,988,272	10,635,103	32,623,375
3	N06	PSYCHOANALEPTICS	17,406,530	13,671,954	31,078,484
4	J01	ANTIBACTERIALS FOR SYSTEMIC USE	10,883,002	12,919,160	23,802,162
5	N02	ANALGESICS	16,252,593	5,898,504	22,151,097
6	A02	DRUGS FOR ACID RELATED DISORDERS	15,437,828	6,552,738	21,990,566
7	A10	DRUGS USED IN DIABETES	12,741,240	2,368,746	15,109,986
8	R03	DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES	12,281,965	1,641,774	13,923,739
9	B01	ANTITHROMBOTIC AGENTS	9,349,688	966,082	10,315,770
10	N05	PSYCHOLEPTICS	7,459,669	1,981,554	9,441,223
11	C07	BETA BLOCKING AGENTS	6,535,711	2,329,664	8,865,375
12	C08	CALCIUM CHANNEL BLOCKERS	6,292,793	2,512,803	8,805,596
13	S01	OPHTHALMOLOGICALS	6,827,462	1,600,184	8,427,646
14	M01	ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS	3,497,680	3,165,132	6,662,812
15	G03	SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM	2,218,922	3,340,083	5,559,005
16	H02	CORTICOSTEROIDS FOR SYSTEMIC USE	2,238,155	1,952,798	4,190,953
17	D07	CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS	2,315,797	1,718,866	4,034,663
18	C01	CARDIAC THERAPY	2,856,511	601,233	3,457,744
19	N03	ANTIEPILEPTICS	2,314,793	754,752	3,069,545
20	C03	DIURETICS	2,413,538	550,230	2,963,768
21	C02	ANTIHYPERTENSIVES	1,846,071	565,272	2,411,343
22	G04	UROLOGICALS	1,732,277	372,675	2,104,952
23	M04	ANTIGOUT PREPARATIONS	1,243,050	831,017	2,074,067
24	M05	DRUGS FOR TREATMENT OF BONE DISEASES	1,828,457	213,099	2,041,556
25	H03	THYROID THERAPY	1,133,947	899,058	2,033,005
26	L01	ANTINEOPLASTIC AGENTS	1,845,238	96,087	1,941,325
27	L04	IMMUNOSUPPRESSANTS	1,730,434	143,046	1,873,480
28	A06	DRUGS FOR CONSTIPATION	1,462,095	79,265	1,541,360
29	N04	ANTI-PARKINSON DRUGS	1,313,119	184,910	1,498,029
30	J05	ANTIVIRALS FOR SYSTEMIC USE	963,834	498,816	1,462,650
31	A04	ANTIEMETICS AND ANTINAUSEANTS	922,483	477,713	1,400,196
32	A03	DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS	814,447	388,299	1,202,746
33	L02	ENDOCRINE THERAPY	781,256	320,858	1,102,114
34	B03	ANTIANEMIC PREPARATIONS	960,463	121,621	1,082,084
35	S02	OTOLOGICALS	560,133	509,960	1,070,093
36	A07	ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS	888,902	54,779	943,681
37	N07	OTHER NERVOUS SYSTEM DRUGS	677,264	4,439	681,703
38	D10	ANTI-ACNE PREPARATIONS	238,954	156,822	395,776
39	A12	MINERAL SUPPLEMENTS	315,712	52,553	368,265
40	M03	MUSCLE RELAXANTS	281,565	63,206	344,771
41	D05	ANTIPSORIATICS	264,672	58,159	322,831
42	G02	OTHER GYNECOLOGICALS	197,440	6,120	203,560
43	A09	DIGESTIVES, INCL. ENZYMES	174,608	714	175,322
44	A11	VITAMINS	135,115	36,042	171,157
45	H01	PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES	164,390	13	164,403
46	L03	IMMUNOSTIMULANTS	153,383	186	153,569
47	A01	STOMATOLOGICAL PREPARATIONS	98,483	50,643	149,126
48	D01	ANTIFUNGALS FOR DERMATOLOGICAL USE	71,508	50,718	122,226
49	V03	ALL OTHER THERAPEUTIC PRODUCTS	111,620	10,519	122,139
50	R05	COUGH AND COLD PREPARATIONS	76,974	44,995	121,969

[^] Excludes Section 100 prescriptions supplied through Remote Area Aboriginal Health Services.

Table 8: ATC Main Groups Comparison for PBS Subsidised Prescriptions, Government Cost, Patient Contribution and Average Price, 2018-19 and 2019-20

Section 85 and Section 100A, including Drs Bag, excluding under co-payment prescriptions

ATC Group Level 1	PBS Subsidised Prescriptions				Government Cost				Patient Contribution***			
	2018-19	2019-20	Prescriptions Change	Percentage Change	2018-19	2019-20	Gov Cost Change	Percentage Change	2018-19	2019-20	Patient Contribution Change	Percentage Change
ALIMENTARY TRACT AND METABOLISM	32,321,199	33,040,857	719,658	2.2%	\$ 955,293,426	\$ 984,020,447	\$ 28,727,021	3.0%	\$ 252,838,085	\$ 269,341,803	\$ 16,503,718	6.5%
BLOOD AND BLOOD FORMING ORGANS	9,902,014	10,388,487	486,473	4.9%	\$ 687,466,509	\$ 754,705,281	\$ 67,238,772	9.8%	\$ 100,364,499	\$ 109,515,184	\$ 9,150,685	9.1%
CARDIOVASCULAR SYSTEM	64,254,428	65,309,786	1,055,358	1.6%	\$ 932,284,192	\$ 977,776,191	\$ 45,491,999	4.9%	\$ 375,916,379	\$ 361,508,837	-\$ 14,407,543	-3.8%
DERMATOLOGICALS	2,884,101	2,982,967	98,866	3.4%	\$ 67,775,547	\$ 71,143,065	\$ 3,367,517	5.0%	\$ 27,047,730	\$ 29,029,720	\$ 1,981,991	7.3%
GENITO URINARY SYSTEM AND SEX HORMONES	3,974,563	4,148,639	174,076	4.4%	\$ 239,636,956	\$ 246,636,992	\$ 7,000,036	2.9%	\$ 38,204,480	\$ 39,692,646	\$ 1,488,167	3.9%
SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	3,564,227	3,615,132	50,905	1.4%	\$ 169,662,293	\$ 180,680,697	\$ 11,018,404	6.5%	\$ 22,920,234	\$ 23,355,098	\$ 434,864	1.9%
ANTIINFECTIVES FOR SYSTEMIC USE	12,680,243	11,979,502	- 700,741	-5.5%	\$ 1,228,744,760	\$ 983,965,280	-\$ 244,779,480	-19.9%	\$ 84,915,312	\$ 81,964,420	-\$ 2,950,892	-3.5%
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	4,182,152	4,510,311	328,159	7.8%	\$ 4,385,490,769	\$ 5,020,106,991	\$ 634,616,222	14.5%	\$ 63,215,435	\$ 70,691,864	\$ 7,476,429	11.8%
MUSCULO-SKELETAL SYSTEM	6,901,661	6,851,278	- 50,383	-0.7%	\$ 421,045,500	\$ 438,797,043	\$ 17,751,542	4.2%	\$ 44,022,139	\$ 44,877,851	\$ 855,712	1.9%
NERVOUS SYSTEM	45,155,419	45,444,822	289,403	0.6%	\$ 1,223,269,312	\$ 1,231,269,627	\$ 8,000,315	0.7%	\$ 296,021,498	\$ 291,025,494	-\$ 4,996,003	-1.7%
ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS	77,366	72,937	- 4,429	-5.7%	\$ 2,548,855	\$ 2,790,722	\$ 241,867	9.5%	\$ 630,156	\$ 578,729	-\$ 51,427	-8.2%
RESPIRATORY SYSTEM	11,575,975	12,396,771	820,796	7.1%	\$ 647,093,321	\$ 821,783,348	\$ 174,690,028	27.0%	\$ 133,023,273	\$ 151,513,441	\$ 18,490,168	13.9%
SENSORY ORGANS	7,309,502	7,408,131	98,629	1.3%	\$ 655,985,305	\$ 710,537,867	\$ 54,552,562	8.3%	\$ 41,409,609	\$ 42,338,916	\$ 929,307	2.2%
VARIOUS	197,684	194,230	- 3,454	-1.7%	\$ 77,581,200	\$ 78,550,229	\$ 969,029	1.2%	\$ 3,388,703	\$ 3,554,244	\$ 165,541	4.9%
UNLESS OTHERWISE CLASSIFIED	134,978	125,822	- 9,156	-6.8%	\$ 4,425,566	\$ 4,337,205	-\$ 88,361	-2.0%	\$ 918,438	\$ 848,544	-\$ 69,894	-7.6%
TOTAL	205,115,512	208,469,672	3,354,160	1.6%	\$ 11,698,303,510	\$ 12,507,100,984	\$ 808,797,474	6.9%	\$ 1,484,835,968	\$ 1,519,836,790	\$ 35,000,822	2.4%

ATC Group Level 1	Total Cost*				Average Price**			
	2018-19	2019-20	Total Cost Change	Percentage Change	2018-19	2019-20	Ave Price Change	Percentage Change
ALIMENTARY TRACT AND METABOLISM	\$ 1,208,131,511	\$ 1,253,362,250	\$ 45,230,739	3.7%	\$ 37.38	\$ 37.93	\$ 0.55	1.5%
BLOOD AND BLOOD FORMING ORGANS	\$ 787,831,008	\$ 864,220,465	\$ 76,389,457	9.7%	\$ 79.56	\$ 83.19	\$ 3.63	4.6%
CARDIOVASCULAR SYSTEM	\$ 1,308,200,571	\$ 1,339,285,028	\$ 31,084,456	2.4%	\$ 20.36	\$ 20.51	\$ 0.15	0.7%
DERMATOLOGICALS	\$ 94,823,277	\$ 100,172,785	\$ 5,349,508	5.6%	\$ 32.88	\$ 33.58	\$ 0.70	2.1%
GENITO URINARY SYSTEM AND SEX HORMONES	\$ 277,841,435	\$ 286,329,638	\$ 8,488,203	3.1%	\$ 69.90	\$ 69.02	-\$ 0.88	-1.3%
SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	\$ 192,582,527	\$ 204,035,795	\$ 11,453,268	5.9%	\$ 54.03	\$ 56.44	\$ 2.41	4.5%
ANTIINFECTIVES FOR SYSTEMIC USE	\$ 1,313,660,072	\$ 1,065,929,699	-\$ 247,730,372	-18.9%	\$ 103.60	\$ 88.98	-\$ 14.62	-14.1%
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	\$ 4,448,706,204	\$ 5,090,798,855	\$ 642,092,651	14.4%	\$ 1,063.74	\$ 1,128.70	\$ 64.96	6.1%
MUSCULO-SKELETAL SYSTEM	\$ 465,067,639	\$ 483,674,893	\$ 18,607,254	4.0%	\$ 67.38	\$ 70.60	\$ 3.22	4.8%
NERVOUS SYSTEM	\$ 1,519,290,809	\$ 1,522,295,122	\$ 3,004,312	0.2%	\$ 33.65	\$ 33.50	-\$ 0.15	-0.4%
ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS	\$ 3,179,011	\$ 3,369,451	\$ 190,440	6.0%	\$ 41.09	\$ 46.20	\$ 5.11	12.4%
RESPIRATORY SYSTEM	\$ 780,116,594	\$ 973,296,789	\$ 193,180,195	24.8%	\$ 67.39	\$ 78.51	\$ 11.12	16.5%
SENSORY ORGANS	\$ 697,394,913	\$ 752,876,782	\$ 55,481,869	8.0%	\$ 95.41	\$ 101.63	\$ 6.22	6.5%
VARIOUS	\$ 80,969,903	\$ 82,104,473	\$ 1,134,570	1.4%	\$ 409.59	\$ 422.72	\$ 13.13	3.2%
UNLESS OTHERWISE CLASSIFIED	\$ 5,344,004	\$ 5,185,749	-\$ 158,255	-3.0%	\$ 39.59	\$ 41.21	\$ 1.62	4.1%
TOTAL	\$ 13,183,139,478	\$ 14,026,937,774	\$ 843,798,296	6.4%	\$ 64.27	\$ 67.29	\$ 3.01	4.7%

* Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions.

** Average Price is Total Cost divided by PBS Subsidised Prescriptions.

*** The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

^ Excludes Section 100 prescriptions supplied through Remote Area Aboriginal Health Services.

Table 9(a): Top 35 Drugs Sorted by Highest Change to Government Cost, 2018-19 and 2019-20
 Section 85 and Section 100[^], including Drs Bag, excluding under co-payment prescriptions

Rank	Drug Name	2018-19					2019-20					Government Cost Change	Government Cost Change Percentage
		PBS Subsidised Prescriptions	Government Cost	Patient Contribution***	Total Cost*	Ave. Price**	PBS Subsidised Prescriptions	Government Cost	Patient Contribution***	Total Cost*	Ave. Price**		
1	PEMBROLIZUMAB	24,810	\$ 212,942,681	\$ 116,610	\$ 213,059,291	\$ 8,588	37,568	\$ 331,481,924	\$ 166,331	\$ 331,648,255	\$ 8,828	\$ 118,539,243	55.67%
2	NIVOLUMAB	52,202	\$ 258,736,972	\$ 206,693	\$ 258,943,665	\$ 4,960	50,323	\$ 333,970,002	\$ 236,244	\$ 334,206,247	\$ 6,641	\$ 75,233,030	29.08%
3	BICTEGRAVIR + EMTRICITABINE + TENOFOVIR ALAFENAMIDE	7,440	\$ 13,062,741	\$ 221,906	\$ 13,284,647	\$ 1,786	41,963	\$ 74,147,901	\$ 1,245,984	\$ 75,393,885	\$ 1,797	\$ 61,085,160	467.63%
4	LUMACAFTOR + IVACAFTOR	5,595	\$ 104,787,685	\$ 75,178	\$ 104,862,863	\$ 18,742	8,607	\$ 159,493,461	\$ 117,799	\$ 159,611,261	\$ 18,544	\$ 54,705,776	52.21%
5	PALBOCICLIB	602	\$ 2,566,033	\$ 13,718	\$ 2,579,750	\$ 4,285	11,319	\$ 47,717,548	\$ 239,731	\$ 47,957,278	\$ 4,237	\$ 45,151,515	1,759.58%
6	CLADRIBINE	1,832	\$ 25,700,342	\$ 38,769	\$ 25,739,111	\$ 14,050	4,264	\$ 68,743,467	\$ 101,918	\$ 68,845,385	\$ 16,146	\$ 43,043,125	167.48%
7	APIXABAN	2,000,307	\$ 162,347,814	\$ 23,261,092	\$ 185,608,906	\$ 93	2,480,138	\$ 201,261,551	\$ 29,244,594	\$ 230,506,145	\$ 93	\$ 38,913,737	23.97%
8	GUSELKUMAB	1,777	\$ 6,672,960	\$ 55,611	\$ 6,728,571	\$ 3,786	11,344	\$ 42,603,540	\$ 355,455	\$ 42,958,995	\$ 3,787	\$ 35,930,580	538.45%
9	OCRELIZUMAB	6,202	\$ 105,048,591	\$ 195,312	\$ 105,243,904	\$ 16,969	8,133	\$ 140,315,361	\$ 261,442	\$ 140,576,803	\$ 17,285	\$ 35,266,769	33.57%
10	AFLIBERCEPT	273,373	\$ 338,542,794	\$ 4,084,136	\$ 342,626,930	\$ 1,253	299,955	\$ 372,844,440	\$ 4,562,127	\$ 377,406,567	\$ 1,258	\$ 34,301,646	10.13%
11	USTEKINUMAB	25,554	\$ 177,522,843	\$ 759,539	\$ 178,282,382	\$ 6,977	29,392	\$ 209,733,381	\$ 885,599	\$ 210,618,980	\$ 7,166	\$ 32,210,538	18.14%
12	ATEZOLIZUMAB	3,941	\$ 30,045,314	\$ 24,207	\$ 30,069,521	\$ 7,630	8,232	\$ 61,979,194	\$ 49,557	\$ 62,028,751	\$ 7,535	\$ 31,933,880	106.29%
13	DULAGLUTIDE	153,837	\$ 17,241,862	\$ 2,843,263	\$ 20,085,125	\$ 131	382,684	\$ 43,120,177	\$ 6,818,027	\$ 49,938,204	\$ 130	\$ 25,878,314	150.09%
14	DENOSUMAB	759,593	\$ 211,454,191	\$ 8,968,723	\$ 220,422,915	\$ 290	857,062	\$ 236,822,977	\$ 10,260,220	\$ 247,083,197	\$ 288	\$ 25,368,786	12.00%
15	BARICITINIB	10,829	\$ 13,491,418	\$ 235,410	\$ 13,726,829	\$ 1,268	31,018	\$ 38,654,329	\$ 684,537	\$ 39,338,866	\$ 1,268	\$ 25,162,911	186.51%
16	OBINUTUZUMAB	3,682	\$ 20,071,087	\$ 13,781	\$ 20,084,868	\$ 5,455	7,661	\$ 41,788,505	\$ 31,277	\$ 41,819,782	\$ 5,459	\$ 21,717,418	108.20%
17	LENALIDOMIDE	23,777	\$ 144,798,615	\$ 369,661	\$ 145,168,276	\$ 6,105	28,133	\$ 165,780,317	\$ 457,077	\$ 166,237,394	\$ 5,909	\$ 20,981,702	14.49%
18	SARALIZUMAB	2,036	\$ 6,767,689	\$ 52,576	\$ 6,820,265	\$ 3,350	8,117	\$ 27,025,902	\$ 191,243	\$ 27,217,146	\$ 3,353	\$ 20,258,214	299.34%
19	SACUBITRIL + VALSARTAN	228,875	\$ 42,354,753	\$ 3,011,774	\$ 45,366,527	\$ 198	336,934	\$ 62,355,840	\$ 4,494,350	\$ 66,850,191	\$ 198	\$ 20,001,087	47.22%
20	OSIMERTINIB	1,216	\$ 9,914,412	\$ 23,104	\$ 9,937,516	\$ 8,172	3,710	\$ 29,618,302	\$ 67,889	\$ 29,686,190	\$ 8,002	\$ 19,703,890	198.74%
21	INSULIN DEGLUDEC + INSULIN ASPART	41,301	\$ 14,444,828	\$ 574,508	\$ 15,019,336	\$ 364	96,063	\$ 33,785,230	\$ 1,250,807	\$ 35,036,037	\$ 365	\$ 19,340,402	133.89%
22	VEDOLIZUMAB	16,268	\$ 50,389,492	\$ 518,535	\$ 50,908,027	\$ 3,129	22,243	\$ 68,869,316	\$ 721,418	\$ 69,590,734	\$ 3,129	\$ 18,479,824	36.67%
23	IBRUTINIB	13,555	\$ 125,931,098	\$ 199,563	\$ 126,130,661	\$ 9,305	15,479	\$ 142,932,301	\$ 223,581	\$ 143,155,882	\$ 9,248	\$ 17,001,203	13.50%
24	FLUTICASON FUROATE + UMECLIDINIUM + VILANTEROL	195,837	\$ 17,209,067	\$ 1,861,608	\$ 19,070,675	\$ 97	393,442	\$ 34,202,279	\$ 3,813,426	\$ 38,015,705	\$ 97	\$ 16,993,212	98.75%
25	AVELUMAB	341	\$ 2,129,071	\$ 1,823	\$ 2,130,893	\$ 6,249	2,830	\$ 17,801,246	\$ 8,709	\$ 17,809,956	\$ 6,293	\$ 15,672,176	736.10%
26	TOFACITINIB	50,119	\$ 62,519,401	\$ 1,003,489	\$ 63,522,889	\$ 1,267	62,002	\$ 77,281,677	\$ 1,293,622	\$ 78,575,299	\$ 1,267	\$ 14,762,276	23.61%
27	IPILIMUMAB	2,854	\$ 81,646,006	\$ 33,748	\$ 81,679,754	\$ 28,619	3,894	\$ 96,066,573	\$ 41,852	\$ 96,108,426	\$ 24,681	\$ 14,420,567	17.66%
28	LENVATINIB	1,821	\$ 10,089,165	\$ 33,152	\$ 10,122,317	\$ 5,559	3,518	\$ 24,328,485	\$ 64,294	\$ 24,392,778	\$ 6,934	\$ 14,239,319	141.13%
29	VENETOCLAX	230	\$ 1,382,847	\$ 4,118	\$ 1,386,966	\$ 6,030	2,168	\$ 15,110,078	\$ 41,479	\$ 15,151,557	\$ 6,989	\$ 13,727,231	992.68%
30	SOFOSBUVIR + VELPATASVIR + VOXILAPREVIR	889	\$ 11,351,623	\$ 20,859	\$ 11,372,482	\$ 12,792	1,987	\$ 25,046,015	\$ 48,555	\$ 25,094,569	\$ 12,629	\$ 13,694,391	120.64%
31	GLECAPREVIR + PIBRENTASVIR	9,191	\$ 173,310,050	\$ 213,699	\$ 173,523,749	\$ 18,880	9,945	\$ 186,524,509	\$ 246,061	\$ 186,770,570	\$ 18,780	\$ 13,214,459	7.62%
32	PEGFILGRASTIM	58,122	\$ 68,830,618	\$ 1,598,175	\$ 70,428,793	\$ 1,212	69,801	\$ 81,999,903	\$ 1,990,319	\$ 83,990,222	\$ 1,203	\$ 13,169,285	19.13%
33	RANIBIZUMAB	167,580	\$ 191,977,178	\$ 2,210,665	\$ 194,187,844	\$ 1,159	178,604	\$ 204,683,547	\$ 2,407,211	\$ 207,090,758	\$ 1,160	\$ 12,706,369	6.62%
34	GUANFACINE	51,796	\$ 5,596,169	\$ 884,322	\$ 6,480,491	\$ 125	165,727	\$ 17,921,767	\$ 2,846,434	\$ 20,768,201	\$ 125	\$ 12,325,598	220.25%
35	POMALIDOMIDE	2,363	\$ 24,801,143	\$ 34,505	\$ 24,835,648	\$ 10,510	3,541	\$ 37,062,373	\$ 52,269	\$ 37,114,642	\$ 10,481	\$ 12,261,230	49.44%

* Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions.

** Average Price is Total Cost divided by PBS Subsidised Prescriptions.

*** The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

[^] Excludes Section 100 prescriptions supplied through Remote Area Aboriginal Health Services.

Table 9(b): Top 35 Drugs Sorted by Highest Change to Subsidised Script Volume, 2018-19 and 2019-20
 Section 85 and Section 100[^], including Drs Bag, excluding under co-payment prescriptions

Rank	Drug Name	2018-19					2019-20					Prescription Volume Change	Prescription Volume Change Percentage
		PBS Subsidised Prescriptions	Government Cost	Patient Contribution***	Total Cost*	Ave. Price**	PBS Subsidised Prescriptions	Government Cost	Patient Contribution***	Total Cost*	Ave. Price**		
1	PANTOPRAZOLE	5,000,593	\$ 46,319,884	\$ 25,102,569	\$ 71,422,453	\$ 14.28	5,691,237	\$ 50,476,431	\$ 28,530,358	\$ 79,006,789	\$ 13.88	690,644	13.81%
2	ROSUVASTATIN	7,293,100	\$ 89,294,791	\$ 38,883,322	\$ 128,178,113	\$ 17.58	7,800,628	\$ 94,490,269	\$ 41,712,052	\$ 136,202,321	\$ 17.46	507,528	6.96%
3	APIXABAN	2,000,307	\$ 162,347,814	\$ 23,261,092	\$ 185,608,906	\$ 92.79	2,480,138	\$ 201,261,551	\$ 29,244,594	\$ 230,506,145	\$ 92.94	479,831	23.99%
4	SALBUTAMOL	2,826,933	\$ 41,973,649	\$ 12,169,822	\$ 54,143,471	\$ 19.15	3,058,953	\$ 47,570,183	\$ 13,391,906	\$ 60,962,089	\$ 19.93	232,020	8.21%
5	BUDESONIDE + FORMOTEROL (EFORMOTEROL)	1,772,425	\$ 61,568,250	\$ 33,268,956	\$ 94,837,205	\$ 53.51	2,002,220	\$ 67,854,969	\$ 40,297,136	\$ 108,152,105	\$ 54.02	229,795	12.97%
6	DULAGLUTIDE	153,837	\$ 17,241,862	\$ 2,843,263	\$ 20,085,125	\$ 130.56	382,684	\$ 43,120,177	\$ 6,818,027	\$ 49,938,204	\$ 130.49	228,847	148.76%
7	FLUTICASONE FUROATE + UMECLIDINIUM + VILANTEROL	195,837	\$ 17,209,067	\$ 1,861,608	\$ 19,070,675	\$ 97.38	393,442	\$ 34,202,279	\$ 3,813,426	\$ 38,015,705	\$ 96.62	197,605	100.90%
8	EMPAGLIFLOZIN	667,079	\$ 30,317,196	\$ 10,929,129	\$ 41,246,325	\$ 61.83	857,694	\$ 38,516,429	\$ 14,084,290	\$ 52,600,719	\$ 61.33	190,615	28.57%
9	RIVAROXABAN	1,899,090	\$ 140,075,145	\$ 26,236,969	\$ 166,312,114	\$ 87.57	2,083,921	\$ 149,937,278	\$ 29,241,833	\$ 179,179,110	\$ 85.98	184,831	9.73%
10	AMLODIPINE	2,510,401	\$ 18,323,293	\$ 12,977,424	\$ 31,300,717	\$ 12.47	2,675,707	\$ 19,882,634	\$ 13,896,241	\$ 33,778,875	\$ 12.62	165,306	6.58%
11	ESCITALOPRAM	1,935,745	\$ 16,390,382	\$ 10,610,144	\$ 27,000,526	\$ 13.95	2,089,633	\$ 17,932,521	\$ 11,520,696	\$ 29,453,216	\$ 14.09	153,888	7.95%
12	DUTASTERIDE + TAMSULOSIN	1,062,307	\$ 28,749,106	\$ 5,361,373	\$ 34,110,479	\$ 32.11	1,215,817	\$ 33,040,388	\$ 6,086,308	\$ 39,126,696	\$ 32.18	153,510	14.45%
13	ATORVASTATIN	7,388,588	\$ 65,832,106	\$ 38,314,123	\$ 104,146,228	\$ 14.10	7,540,302	\$ 68,410,099	\$ 39,223,649	\$ 107,633,748	\$ 14.27	151,714	2.05%
14	BISOPROLOL	1,167,728	\$ 17,375,192	\$ 5,732,118	\$ 23,107,310	\$ 19.79	1,318,636	\$ 19,796,564	\$ 6,459,424	\$ 26,255,988	\$ 19.91	150,908	12.92%
15	EMPAGLIFLOZIN + METFORMIN	516,156	\$ 23,469,198	\$ 9,882,658	\$ 33,351,856	\$ 64.62	663,012	\$ 29,751,309	\$ 12,778,215	\$ 42,529,524	\$ 64.15	146,856	28.45%
16	MIRTAZAPINE	1,892,119	\$ 20,085,419	\$ 9,432,300	\$ 29,517,719	\$ 15.60	2,037,113	\$ 21,798,288	\$ 10,124,217	\$ 31,922,505	\$ 15.67	144,994	7.66%
17	SERTRALINE	2,027,070	\$ 16,697,675	\$ 10,929,901	\$ 27,627,577	\$ 13.63	2,153,769	\$ 18,035,423	\$ 11,668,604	\$ 29,704,027	\$ 13.79	126,699	6.25%
18	TAPENTADOL	702,158	\$ 23,885,556	\$ 5,964,323	\$ 29,849,878	\$ 42.51	819,187	\$ 27,770,921	\$ 6,595,908	\$ 34,366,829	\$ 41.95	117,029	16.67%
19	GUANFACINE	51,796	\$ 5,596,169	\$ 884,322	\$ 6,480,491	\$ 125.12	165,727	\$ 17,921,767	\$ 2,846,434	\$ 20,768,201	\$ 125.32	113,931	219.96%
20	FLUTICASONE FUROATE + VILANTEROL	605,503	\$ 28,911,585	\$ 10,670,084	\$ 39,581,669	\$ 65.37	715,769	\$ 33,362,759	\$ 13,576,419	\$ 46,939,179	\$ 65.58	110,266	18.21%
21	LINAGLIPTIN	455,132	\$ 22,481,596	\$ 4,708,478	\$ 27,190,073	\$ 59.74	564,298	\$ 27,930,593	\$ 5,871,611	\$ 33,802,204	\$ 59.90	109,166	23.99%
22	SACUBITRIL + VALSARTAN	228,875	\$ 42,354,753	\$ 3,011,774	\$ 45,366,527	\$ 198.22	336,934	\$ 62,355,840	\$ 4,494,350	\$ 66,850,191	\$ 198.41	108,059	47.21%
23	TELMISARTAN	2,141,329	\$ 19,468,324	\$ 11,688,259	\$ 31,156,583	\$ 14.55	2,247,646	\$ 20,727,677	\$ 12,325,092	\$ 33,052,770	\$ 14.71	106,317	4.97%
24	CANDESARTAN	2,070,435	\$ 18,329,708	\$ 11,121,879	\$ 29,451,587	\$ 14.22	2,174,232	\$ 19,471,656	\$ 11,739,904	\$ 31,211,560	\$ 14.36	103,797	5.01%
25	SITAGLIPTIN + METFORMIN	1,394,824	\$ 57,609,188	\$ 23,507,478	\$ 81,116,666	\$ 58.16	1,497,917	\$ 56,869,478	\$ 25,382,602	\$ 82,252,080	\$ 54.91	103,093	7.39%
26	HYALURONATE SODIUM	211,799	\$ 6,236,211	\$ 1,032,338	\$ 7,268,549	\$ 34.32	311,994	\$ 9,247,039	\$ 1,485,104	\$ 10,732,144	\$ 34.40	100,195	47.31%
27	DENOSUMAB	759,593	\$ 211,454,191	\$ 8,968,723	\$ 220,422,915	\$ 290.19	857,062	\$ 236,822,977	\$ 10,260,220	\$ 247,083,197	\$ 288.29	97,469	12.83%
28	DULOXETINE	1,019,344	\$ 13,551,342	\$ 5,225,862	\$ 18,777,203	\$ 18.42	1,102,516	\$ 14,865,190	\$ 5,596,797	\$ 20,461,988	\$ 18.56	83,172	8.16%
29	EMPAGLIFLOZIN + LINAGLIPTIN	87,783	\$ 5,709,234	\$ 1,705,754	\$ 7,414,988	\$ 84.47	160,568	\$ 10,380,911	\$ 3,128,883	\$ 13,509,794	\$ 84.14	72,785	82.91%
30	PERINDOPRIL + AMLODIPINE	1,370,192	\$ 14,759,347	\$ 7,649,931	\$ 22,409,278	\$ 16.35	1,441,268	\$ 15,704,898	\$ 8,111,688	\$ 23,816,586	\$ 16.52	71,076	5.19%
31	METHYLPHENIDATE	688,633	\$ 25,935,110	\$ 11,539,642	\$ 37,474,752	\$ 54.42	757,683	\$ 27,912,910	\$ 13,408,219	\$ 41,321,129	\$ 54.54	69,050	10.03%
32	METFORMIN	3,231,043	\$ 33,793,787	\$ 15,493,589	\$ 49,287,375	\$ 15.25	3,299,533	\$ 35,159,985	\$ 15,793,979	\$ 50,953,965	\$ 15.44	68,490	2.12%
33	AMITRIPTYLINE	1,556,949	\$ 14,809,294	\$ 7,578,586	\$ 22,387,880	\$ 14.38	1,625,160	\$ 15,717,950	\$ 7,882,639	\$ 23,600,589	\$ 14.52	68,211	4.38%
34	FLUOXETINE	979,513	\$ 12,423,866	\$ 5,431,240	\$ 17,855,105	\$ 18.23	1,045,509	\$ 13,415,852	\$ 5,826,391	\$ 19,242,242	\$ 18.40	65,996	6.74%
35	METOPROLOL TARTRATE	1,718,782	\$ 14,441,957	\$ 8,328,696	\$ 22,770,653	\$ 13.25	1,782,526	\$ 15,231,934	\$ 8,668,113	\$ 23,900,047	\$ 13.41	63,744	3.71%

* Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions.

** Average Price is Total Cost divided by PBS Subsidised Prescriptions.

*** The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

[^] Excludes Section 100 prescriptions supplied through Remote Area Aboriginal Health Services.

Table 10(a): PBS Section 85 Prescription Volume, 2016-17 to 2019-20

Section 85 only, including Drs Bag and under co-payment prescriptions

Prescription Type	2016-17	2017-18	2018-19	2019-20
Over Co-payment	199,784,732	201,433,697	202,302,592	205,477,610
Under Co-payment	86,196,957	89,436,537	93,868,330	96,321,324
Total	285,981,689	290,870,234	296,170,922	301,798,934





Table 10(b): PBS Section 85 expenditure, 2016-17 to 2019-20

Section 85 only, including Drs Bag, excluding under co-payment prescriptions

Expenditure Type	2016-17	2017-18	2018-19	2019-20
Government Cost	\$ 8,890,241,686	\$ 8,464,094,754	\$ 8,211,729,252	\$ 8,552,660,248
Patient Contribution*	\$ 1,366,216,381	\$ 1,415,449,913	\$ 1,440,195,122	\$ 1,471,034,036
Total Cost**	\$ 10,256,458,067	\$ 9,879,544,667	\$ 9,651,924,374	\$ 10,023,694,284



* The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

** Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions.

Table 11: PBS Prescriptions and Government Cost by Formulary, 2019-20

Section 85 and Section 100[^], including under co-payment prescriptions and Drs Bag

Formulary Group ¹	PBS Subsidised Prescriptions	Under co-payment Prescriptions	Total Prescriptions	Percentage	Government Cost	Percentage
F1	25,838,240	3,027,961	28,866,201	9.5%	\$ 7,399,221,923	59.2%
F2	171,517,758	91,891,411	263,409,169	86.4%	\$ 3,893,491,377	31.1%
Combination Drugs ²	10,981,655	1,420,938	12,402,593	4.1%	\$ 1,209,908,172	9.7%
Other ³	132,019	33,875	165,894	0.1%	\$ 4,479,512	0.0%
Total	208,469,672	96,374,185	304,843,857	100.0%	\$ 12,507,100,984	100.0%

Notes:

1. The National Health Act 1953 provides that listed drugs be assigned to formularies identified as F1 or F2. Generally F1 is intended for single brand drugs and F2 for drugs that have multiple brands, or are in a therapeutic group with other drugs with multiple brands. Drugs on F2 are subject to the provisions of the Act relating to statutory price reductions, price disclosure and guarantee of supply. Allocation to F1 or F2 is determined by legislative instrument.
 2. Combination Drugs are not allocated to any formulary.
 3. The category 'Other' includes extemporaneously prepared items.
- [^] Excludes Section 100 prescriptions supplied through Remote Area Aboriginal Health Services.

Table 12(a): Top 20 Responsible Persons by Total Cost, 2019-20

Section 85 and Section 100[^] excluding Efficient Funding of Chemotherapy items, including Drs Bag and under co-payment prescriptions

Rank	Responsible Person	PBS Subsidised Prescriptions	Under Co-payment Prescriptions	Total PBS Prescriptions	Government Cost	Patient Contribution (Subsidised Prescriptions only) ***	Total Cost*	Derived Ex-Manufacturer Sales **
1	NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LIMITED	4,580,420	1,479,583	6,060,003	\$ 1,019,397,433	\$ 45,097,609	\$ 1,064,495,042	\$ 910,852,812
2	JANSSEN-CILAG PTY LTD	1,974,355	375,959	2,350,314	\$ 806,905,099	\$ 22,664,085	\$ 829,569,184	\$ 709,071,147
3	ALPHAPHARM PTY LTD	35,647,409	18,551,568	54,198,977	\$ 515,567,607	\$ 191,495,515	\$ 707,063,122	\$ 339,882,225
4	APOTEX PTY LTD	36,713,108	16,624,655	53,337,763	\$ 471,098,277	\$ 194,734,125	\$ 665,832,403	\$ 277,878,397
5	BAYER AUSTRALIA LTD	3,136,856	1,077,426	4,214,282	\$ 585,576,036	\$ 44,420,235	\$ 629,996,271	\$ 545,316,710
6	ABBVIE PTY LTD	310,051	31	310,082	\$ 611,788,907	\$ 8,088,411	\$ 619,877,318	\$ 576,410,879
7	PFIZER AUSTRALIA PTY LTD	8,686,390	4,432,877	13,119,267	\$ 448,530,746	\$ 67,335,186	\$ 515,865,933	\$ 396,893,042
8	ASTRAZENECA PTY LTD	9,485,265	3,264,965	12,750,230	\$ 382,794,017	\$ 101,319,785	\$ 484,113,802	\$ 350,606,379
9	GILEAD SCIENCES PTY LIMITED	198,551	-	198,551	\$ 446,326,041	\$ 6,097,891	\$ 452,423,932	\$ 387,279,308
10	BOEHRINGER INGELHEIM PTY LTD	7,721,009	1,707,647	9,428,656	\$ 318,201,659	\$ 79,733,512	\$ 397,935,172	\$ 297,647,072
11	ROCHE PRODUCTS PTY LTD	864,622	190,623	1,055,245	\$ 354,753,514	\$ 8,724,468	\$ 363,477,982	\$ 302,709,716
12	AMGEN AUSTRALIA PTY LIMITED	948,457	60	948,517	\$ 331,889,039	\$ 11,802,286	\$ 343,691,325	\$ 285,663,282
13	GLAXOSMITHKLINE AUSTRALIA PTY LTD	6,214,531	1,002,590	7,217,121	\$ 265,639,728	\$ 76,852,145	\$ 342,491,873	\$ 234,618,273
14	MERCK SHARP & DOHME (AUSTRALIA) PTY LTD	5,385,658	1,435,615	6,821,273	\$ 272,156,704	\$ 63,914,898	\$ 336,071,602	\$ 256,586,573
15	BRISTOL-MYERS SQUIBB AUSTRALIA PTY LTD	2,612,683	681	2,613,364	\$ 298,897,353	\$ 32,014,454	\$ 330,911,807	\$ 272,156,958
16	SANDOZ PTY LTD	14,524,149	16,816,189	31,340,338	\$ 225,791,329	\$ 84,309,143	\$ 310,100,472	\$ 189,762,295
17	SANOFI-AVENTIS AUSTRALIA PTY LTD	8,276,099	3,610,356	11,886,455	\$ 234,459,287	\$ 52,478,937	\$ 286,938,224	\$ 189,753,640
18	VERTEX PHARMACEUTICALS (AUSTRALIA) PTY LTD	14,336	-	14,336	\$ 282,223,285	\$ 215,006	\$ 282,438,291	\$ 271,936,980
19	ARROW PHARMA PTY LTD	16,188,799	7,157,519	23,346,318	\$ 194,418,321	\$ 86,161,001	\$ 280,579,322	\$ 117,052,888
20	MUNDIPHARMA PTY LIMITED	4,229,520	589,417	4,818,937	\$ 185,235,203	\$ 33,706,123	\$ 218,941,326	\$ 152,230,076

* Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions.

** Derived Ex-Manufacturer Sales is derived by subtracting the Wholesale Margin amount from the Price to Pharmacist for Dispensed Quantity (per script).

*** The patient contribution includes the cost to the patient for PBS subsidised prescriptions. The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

[^] Excludes Section 100 prescriptions supplied through Remote Area Aboriginal Health Services.

n.p. - Not Published. Cells with fewer than 6 prescriptions have been suppressed and excluded from totals.

Table 12(b): Top 20 Responsible Persons by PBS Subsidised Prescriptions, 2019-20

Section 85 and Section 100[^] excluding Efficient Funding of Chemotherapy items, including Drs Bag and under co-payment prescriptions

Rank	Responsible Person	PBS Subsidised Prescriptions	Under Co-payment Prescriptions	Total PBS Prescriptions	Government Cost	Patient Contribution (Subsidised Prescriptions only) ***	Total Cost*	Derived Ex-Manufacturer Sales **
1	APOTEX PTY LTD	36,713,108	16,624,655	53,337,763	\$ 471,098,277	\$ 194,734,125	\$ 665,832,403	\$ 277,878,397
2	ALPHAPHARM PTY LTD	35,647,409	18,551,568	54,198,977	\$ 515,567,607	\$ 191,495,515	\$ 707,063,122	\$ 339,882,225
3	ARROW PHARMA PTY LTD	16,188,799	7,157,519	23,346,318	\$ 194,418,321	\$ 86,161,001	\$ 280,579,322	\$ 117,052,888
4	SANDOZ PTY LTD	14,524,149	16,816,189	31,340,338	\$ 225,791,329	\$ 84,309,143	\$ 310,100,472	\$ 189,762,295
5	ASTRAZENECA PTY LTD	9,485,265	3,264,965	12,750,230	\$ 382,794,017	\$ 101,319,785	\$ 484,113,802	\$ 350,606,379
6	PFIZER AUSTRALIA PTY LTD	8,686,390	4,432,877	13,119,267	\$ 448,530,746	\$ 67,335,186	\$ 515,865,933	\$ 396,893,042
7	SANOFI-AVENTIS AUSTRALIA PTY LTD	8,276,099	3,610,356	11,886,455	\$ 234,459,287	\$ 52,478,937	\$ 286,938,224	\$ 189,753,640
8	BOEHRINGER INGELHEIM PTY LTD	7,721,009	1,707,647	9,428,656	\$ 318,201,659	\$ 79,733,512	\$ 397,935,172	\$ 297,647,072
9	GLAXOSMITHKLINE AUSTRALIA PTY LTD	6,214,531	1,002,590	7,217,121	\$ 265,639,728	\$ 76,852,145	\$ 342,491,873	\$ 234,618,273
10	ASPEN PHARMACARE AUSTRALIA PTY LIMITED	5,991,902	5,074,971	11,066,873	\$ 91,297,859	\$ 34,936,934	\$ 126,234,793	\$ 79,443,025
11	MERCK SHARP & DOHME (AUSTRALIA) PTY LTD	5,385,658	1,435,615	6,821,273	\$ 272,156,704	\$ 63,914,898	\$ 336,071,602	\$ 256,586,573
12	NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LIMITED	4,580,420	1,479,583	6,060,003	\$ 1,019,397,433	\$ 45,097,609	\$ 1,064,495,042	\$ 910,852,812
13	MUNDIPHARMA PTY LIMITED	4,229,520	589,417	4,818,937	\$ 185,235,203	\$ 33,706,123	\$ 218,941,326	\$ 152,230,076
14	MYLAN HEALTH PTY LTD	3,491,717	1,491,607	4,983,324	\$ 83,741,207	\$ 19,584,973	\$ 103,326,181	\$ 70,363,453
15	BAYER AUSTRALIA LTD	3,136,856	1,077,426	4,214,282	\$ 585,576,036	\$ 44,420,235	\$ 629,996,271	\$ 545,316,710
16	BRISTOL-MYERS SQUIBB AUSTRALIA PTY LTD	2,612,683	681	2,613,364	\$ 298,897,353	\$ 32,014,454	\$ 330,911,807	\$ 272,156,958
17	SERVIER LABORATORIES (AUST.) PTY LTD	2,284,515	1,369,542	3,654,057	\$ 47,844,007	\$ 13,094,525	\$ 60,938,532	\$ 38,740,612
18	JANSSEN-CILAG PTY LTD	1,974,355	375,959	2,350,314	\$ 806,905,099	\$ 22,664,085	\$ 829,569,184	\$ 709,071,147
19	UPJOHN AUSTRALIA PTY LTD	1,628,213	799,170	2,427,383	\$ 21,597,297	\$ 9,726,450	\$ 31,323,747	\$ 15,636,979
20	TAKEDA PHARMACEUTICALS AUSTRALIA PTY LTD	1,621,338	545,620	2,166,958	\$ 87,346,624	\$ 9,882,081	\$ 97,228,705	\$ 57,375,187

* Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions.

** Derived Ex-Manufacturer Sales is derived by subtracting the Wholesale Margin amount from the Price to Pharmacist for Dispensed Quantity (per script).

*** The patient contribution includes the cost to the patient for PBS subsidised prescriptions. The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

[^] Excludes Section 100 prescriptions supplied through Remote Area Aboriginal Health Services.

Table 12(c): Top 20 Responsible Persons by Total PBS Prescriptions, 2019-20

Section 85 and Section 100[^] excluding Efficient Funding of Chemotherapy items, including Drs Bag and under co-payment prescriptions

Rank	Responsible Person	PBS Subsidised Prescriptions	Under Co-payment Prescriptions	Total PBS Prescriptions	Government Cost	Patient Contribution (Subsidised Prescriptions only) ***	Total Cost*	Derived Ex-Manufacturer Sales **
1	ALPHAPHARM PTY LTD	35,647,409	18,551,568	54,198,977	\$ 515,567,607	\$ 191,495,515	\$ 707,063,122	\$ 339,882,225
2	APOTEX PTY LTD	36,713,108	16,624,655	53,337,763	\$ 471,098,277	\$ 194,734,125	\$ 665,832,403	\$ 277,878,397
3	SANDOZ PTY LTD	14,524,149	16,816,189	31,340,338	\$ 225,791,329	\$ 84,309,143	\$ 310,100,472	\$ 189,762,295
4	ARROW PHARMA PTY LTD	16,188,799	7,157,519	23,346,318	\$ 194,418,321	\$ 86,161,001	\$ 280,579,322	\$ 117,052,888
5	PFIZER AUSTRALIA PTY LTD	8,686,390	4,432,877	13,119,267	\$ 448,530,746	\$ 67,335,186	\$ 515,865,933	\$ 396,893,042
6	ASTRAZENECA PTY LTD	9,485,265	3,264,965	12,750,230	\$ 382,794,017	\$ 101,319,785	\$ 484,113,802	\$ 350,606,379
7	SANOFI-AVENTIS AUSTRALIA PTY LTD	8,276,099	3,610,356	11,886,455	\$ 234,459,287	\$ 52,478,937	\$ 286,938,224	\$ 189,753,640
8	ASPEN PHARMACARE AUSTRALIA PTY LIMITED	5,991,902	5,074,971	11,066,873	\$ 91,297,859	\$ 34,936,934	\$ 126,234,793	\$ 79,443,025
9	BOEHRINGER INGELHEIM PTY LTD	7,721,009	1,707,647	9,428,656	\$ 318,201,659	\$ 79,733,512	\$ 397,935,172	\$ 297,647,072
10	GLAXOSMITHKLINE AUSTRALIA PTY LTD	6,214,531	1,002,590	7,217,121	\$ 265,639,728	\$ 76,852,145	\$ 342,491,873	\$ 234,618,273
11	MERCK SHARP & DOHME (AUSTRALIA) PTY LTD	5,385,658	1,435,615	6,821,273	\$ 272,156,704	\$ 63,914,898	\$ 336,071,602	\$ 256,586,573
12	NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LIMITED	4,580,420	1,479,583	6,060,003	\$ 1,019,397,433	\$ 45,097,609	\$ 1,064,495,042	\$ 910,852,812
13	MYLAN HEALTH PTY LTD	3,491,717	1,491,607	4,983,324	\$ 83,741,207	\$ 19,584,973	\$ 103,326,181	\$ 70,363,453
14	MUNDIPHARMA PTY LIMITED	4,229,520	589,417	4,818,937	\$ 185,235,203	\$ 33,706,123	\$ 218,941,326	\$ 152,230,076
15	BAYER AUSTRALIA LTD	3,136,856	1,077,426	4,214,282	\$ 585,576,036	\$ 44,420,235	\$ 629,996,271	\$ 545,316,710
16	SERVIER LABORATORIES (AUST.) PTY LTD	2,284,515	1,369,542	3,654,057	\$ 47,844,007	\$ 13,094,525	\$ 60,938,532	\$ 38,740,612
17	BRISTOL-MYERS SQUIBB AUSTRALIA PTY LTD	2,612,683	681	2,613,364	\$ 298,897,353	\$ 32,014,454	\$ 330,911,807	\$ 272,156,958
18	UPJOHN AUSTRALIA PTY LTD	1,628,213	799,170	2,427,383	\$ 21,597,297	\$ 9,726,450	\$ 31,323,747	\$ 15,636,979
19	JANSSEN-CILAG PTY LTD	1,974,355	375,959	2,350,314	\$ 806,905,099	\$ 22,664,085	\$ 829,569,184	\$ 709,071,147
20	ASPEN PHARMA PTY LTD	1,472,385	802,152	2,274,537	\$ 25,912,907	\$ 7,974,351	\$ 33,887,258	\$ 16,271,875

* Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions.

** Derived Ex-Manufacturer Sales is derived by subtracting the Wholesale Margin amount from the Price to Pharmacist for Dispensed Quantity (per script).

*** The patient contribution includes the cost to the patient for PBS subsidised prescriptions. The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

[^] Excludes Section 100 prescriptions supplied through Remote Area Aboriginal Health Services.

Table 13: Number of PBS Approved Suppliers, 30 June 2019

Pharmacy State	Number of Community Pharmacies	Number of Private Hospitals	Number of Public Hospitals (Pharmaceutical Reforms)	Number of Dispensing Doctors
NSW	1,895	46	-	3
VIC	1,389	37	70	6
QLD	1,167	38	51	-
SA	460	11	15	1
WA	636	6	19	3
TAS	155	5	4	2
NT	40	1	6	-
ACT	80	5	-	-
Total	5,822	149	165	15

Table 14: PBS Brand Premiums, 2019-20

Section 85 and Section 100[^], excluding Drs Bag and including under co-payment prescriptions

	2019-20
Number of brands listed on the PBS(a)	5,371
Number of brands with a premium(a)	365
% of brands with a premium	6.8%
Average brand premium	\$4.89
Weighted average brand premium(b)	\$4.29
Brand premium range	\$0.25 to \$35.30
Prescriptions (millions) dispensed with a brand premium	35.7
Prescriptions (millions) dispensed at the benchmark level (c)	132.4
% of prescriptions dispensed at benchmark level	78.8%

Notes:

(a) A brand is defined as a unique combination of 'brand name' and 'form and strength' as at June 2019 PBS Schedule.

(b) Weighted average brand premium is calculated by:

total premium value / total prescriptions with a premium = weighted average brand premium

(c) Includes only items where at least one brand is listed with a premium.

[^] Excludes Section 100 prescriptions supplied through Remote Area Aboriginal Health Services.

Table 15(a) PBS/RPBS prescriptions dispensed by Community Pharmacies, 2019-20

Section 85 and Section 100*, excluding Drs Bag and under co-payment prescriptions

Prescription Type	Concessional		General		RPBS		Total	
	Prescriptions	%	Prescriptions	%	Prescriptions	%	Prescriptions	%
Discounted	49,932,721	27%	5,005,263	30%	1,264,407	16%	56,202,391	26%
Non-Discounted	137,948,245	73%	11,739,323	70%	6,662,574	84%	156,350,142	74%
Grand Total	187,880,966	100%	16,744,586	100%	7,926,981	100%	212,552,533	100%

Table 15(b) PBS/RPBS prescriptions by Discount Range dispensed by Community Pharmacies, 2019-20

Section 85 and Section 100*, excluding Drs Bag and under co-payment prescriptions

Discount Range	Concessional		General		RPBS		Total	
	Prescriptions	%	Prescriptions	%	Prescriptions	%	Prescriptions	%
\$1.00	48,468,644	97.1%	4,896,673	97.8%	1,218,948	96.4%	54,584,265	97.1%
0.50 - LT \$1.00	828,677	1.7%	69,506	1.4%	22,506	1.8%	920,689	1.6%
LT 50c	380,086	0.8%	16,892	0.3%	14,957	1.2%	411,935	0.7%
Other	255,314	0.5%	22,192	0.4%	7,996	0.6%	285,502	0.5%
Grand Total	49,932,721	100.0%	5,005,263	100.0%	1,264,407	100.0%	56,202,391	100.0%

* Excludes Section 100 prescriptions supplied through Remote Area Aboriginal Health Services.

Table 16(a): PBS/RPBS Medicines Supplied under Continued Dispensing (ongoing measure only) by Dispensing Pharmacy State, 2019-20**
Section 85^, including under co-payment medicines

Drug Name	NSW	Vic	Qld	SA	WA	Tas	NT	ACT	National
ATORVASTATIN	3,935	2,417	923	490	1,088	494	13	498	9,858
COLESTYRAMINE	19	-	-	-	-	-	-	-	19
EZETIMIBE	205	86	39	21	39	10	-	10	410
FENOFIBRATE	360	146	48	20	65	13	-	18	670
FLUVASTATIN	7	-	-	-	-	-	-	-	7
GEMFIBROZIL	19	7	-	-	-	-	-	-	26
LEVONORGESTREL	71	51	43	24	26	20	-	13	248
LEVONORGESTREL + ETHINYLESTRADIOL	1,610	1,087	660	362	417	411	-	259	4,806
MEDROXYPROGESTERONE	17	7	11	-	6	-	-	-	41
NORETHISTERONE	12	14	-	-	6	-	-	-	32
NORETHISTERONE + ETHINYLESTRADIOL	106	52	37	21	22	32	-	14	284
NORETHISTERONE + MESTRANOL	9	-	-	-	-	-	-	-	9
PRAVASTATIN	231	119	40	15	55	16	-	35	511
ROSUVASTATIN	4,588	2,717	955	578	976	618	6	455	10,893
SIMVASTATIN	792	519	109	109	175	139	-	102	1,945
Grand Total	11,981	7,222	2,865	1,640	2,875	1,753	19	1,404	29,759

Table 16(b): PBS/RPBS Continued Dispensing (ongoing measure only) Medicines Government Cost by Dispensing Pharmacy State, 2019-20**
Section 85^, including under co-payment medicines

Drug Name	NSW	Vic	Qld	SA	WA	Tas	NT	ACT	National
ATORVASTATIN	\$ 24,098	\$ 14,872	\$ 5,494	\$ 3,056	\$ 6,222	\$ 3,174	\$ 72	\$ 2,559	\$ 59,548
COLESTYRAMINE	\$ 1,068	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 1,068
EZETIMIBE	\$ 3,734	\$ 1,604	\$ 654	\$ 430	\$ 740	\$ 166	\$ -	\$ 143	\$ 7,471
FENOFIBRATE	\$ 6,395	\$ 2,593	\$ 825	\$ 345	\$ 1,127	\$ 240	\$ -	\$ 103	\$ 11,629
FLUVASTATIN	\$ 241	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 241
GEMFIBROZIL	\$ 220	\$ 81	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 301
LEVONORGESTREL	\$ 246	\$ 120	\$ 82	\$ 50	\$ 101	\$ 25	\$ -	\$ 50	\$ 674
LEVONORGESTREL + ETHINYLESTRADIOL	\$ 4,238	\$ 2,501	\$ 1,487	\$ 733	\$ 743	\$ 1,374	\$ -	\$ 441	\$ 11,518
MEDROXYPROGESTERONE	\$ 171	\$ 95	\$ 76	\$ -	\$ 38	\$ -	\$ -	\$ -	\$ 380
NORETHISTERONE	\$ 41	\$ 68	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 109
NORETHISTERONE + ETHINYLESTRADIOL	\$ 330	\$ 122	\$ 123	\$ 41	\$ 61	\$ 178	\$ -	\$ 55	\$ 910
NORETHISTERONE + MESTRANOL	\$ 29	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 29
PRAVASTATIN	\$ 1,711	\$ 869	\$ 220	\$ 111	\$ 410	\$ 160	\$ -	\$ 254	\$ 3,736
ROSUVASTATIN	\$ 32,877	\$ 19,714	\$ 6,221	\$ 4,206	\$ 6,642	\$ 5,315	\$ 30	\$ 2,795	\$ 77,801
SIMVASTATIN	\$ 5,071	\$ 3,169	\$ 684	\$ 715	\$ 1,078	\$ 960	\$ -	\$ 545	\$ 12,221
Grand Total	\$ 80,470	\$ 45,808	\$ 15,865	\$ 9,688	\$ 17,162	\$ 11,594	\$ 103	\$ 6,945	\$ 187,635

^ Excludes medicines supplied through Section 100 Remote Area Aboriginal Health Services.

* Includes Anatomical Therapeutic Chemical (ATC) classification G03A and C10A.

** Excludes medicines in other ATC groups covered by Continued Dispensing Arrangements expansion (Emergency Measures) from January 2020. For more information, please see Table 16(c) and 16(d).

*** Small cells with counts less than 6 are suppressed and removed from the total.

Table 16(c): PBS/RPBS Medicines Supplied under Continued Dispensing (both Ongoing and Emergency Measures) by ATC Level 1 and Dispensing Pharmacy State, 2019-20*
Section 85^, including under co-payment medicines

ATC Group Level 1	NSW	Vic	Qld	SA	WA	Tas	NT	ACT	National
ALIMENTARY TRACT AND METABOLISM	9,042	4,411	1,219	696	2,150	504	9	678	18,709
ANTIINFECTIVES FOR SYSTEMIC USE	821	359	105	61	185	33		53	1,617
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	644	178	62	24	112	31	-	42	1,093
BLOOD AND BLOOD FORMING ORGANS	2,538	1,087	407	183	533	116		179	5,043
CARDIOVASCULAR SYSTEM	25,872	14,338	4,307	2,744	6,657	2,342	29	2,230	58,519
DERMATOLOGICALS	447	233	31	26	124	18		41	920
GENITO URINARY SYSTEM AND SEX HORMONES	2,586	1,585	857	509	758	520	7	361	7,183
MUSCULO-SKELETAL SYSTEM	1,976	843	280	180	628	129	-	162	4,198
NERVOUS SYSTEM	9,812	4,850	1,947	938	3,484	886	-	853	22,770
RESPIRATORY SYSTEM	2,994	1,354	1,198	365	706	195	-	214	7,026
SENSORY ORGANS	1,277	743	187	101	362	65		73	2,808
SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	1,133	466	191	96	345	68	-	105	2,404
VARIOUS	44	15	-	-	-	-		-	59
TOTAL	59,186	30,462	10,791	5,923	16,044	4,907	45	4,991	132,349

Table 16(d): PBS/RPBS Continued Dispensing (both Ongoing and Emergency Measures) Government Cost by ATC Level 1 and Dispensing Pharmacy State, 2019-20*
Section 85^, including under co-payment medicines

ATC Group Level 1	NSW	Vic	Qld	SA	WA	Tas	NT	ACT	National
ALIMENTARY TRACT AND METABOLISM	\$ 268,499	\$ 107,064	\$ 30,924	\$ 15,762	\$ 41,106	\$ 10,538	\$ 90	\$ 12,869	\$ 486,852
ANTIINFECTIVES FOR SYSTEMIC USE	\$ 28,089	\$ 4,195	\$ 1,204	\$ 631	\$ 2,325	\$ 615		\$ 1,289	\$ 38,348
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	\$ 432,032	\$ 36,262	\$ 19,626	\$ 19,085	\$ 41,087	\$ 5,471	\$ -	\$ 10,645	\$ 564,208
BLOOD AND BLOOD FORMING ORGANS	\$ 108,609	\$ 41,474	\$ 14,626	\$ 6,356	\$ 18,702	\$ 4,484		\$ 6,994	\$ 201,246
CARDIOVASCULAR SYSTEM	\$ 224,424	\$ 118,851	\$ 34,318	\$ 21,456	\$ 49,681	\$ 19,227	\$ 169	\$ 14,421	\$ 482,546
DERMATOLOGICALS	\$ 7,671	\$ 3,609	\$ 659	\$ 449	\$ 1,644	\$ 192		\$ 372	\$ 14,597
GENITO URINARY SYSTEM AND SEX HORMONES	\$ 18,064	\$ 9,248	\$ 3,456	\$ 2,264	\$ 5,058	\$ 2,170	\$ 27	\$ 1,791	\$ 42,078
MUSCULO-SKELETAL SYSTEM	\$ 31,044	\$ 13,508	\$ 3,912	\$ 3,090	\$ 6,531	\$ 1,526	\$ -	\$ 3,082	\$ 62,692
NERVOUS SYSTEM	\$ 178,956	\$ 61,848	\$ 97,394	\$ 10,805	\$ 36,369	\$ 12,350	\$ -	\$ 8,355	\$ 406,077
RESPIRATORY SYSTEM	\$ 94,514	\$ 35,617	\$ 14,082	\$ 6,254	\$ 17,003	\$ 4,859	\$ -	\$ 4,451	\$ 176,780
SENSORY ORGANS	\$ 20,914	\$ 10,827	\$ 1,702	\$ 1,259	\$ 5,175	\$ 836		\$ 1,001	\$ 41,713
SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	\$ 17,230	\$ 6,524	\$ 2,609	\$ 1,378	\$ 3,894	\$ 825	\$ -	\$ 1,136	\$ 33,597
VARIOUS	\$ 9,028	\$ 2,500	\$ -	\$ -	\$ -	\$ -		\$ -	\$ 11,528
TOTAL	\$ 1,439,073	\$ 451,528	\$ 224,513	\$ 88,790	\$ 228,575	\$ 63,092	\$ 286	\$ 66,406	\$ 2,562,262

^ Excludes medicines supplied through Section 100 Remote Area Aboriginal Health Services.

* Continued Dispensing Emergency Measures came into effect on 13 January 2020.

** Small cells with counts less than 6 are suppressed and removed from the total.

Table 17: Remuneration for Community Pharmacies and Friendly Societies¹ for PBS subsidised prescriptions, 2015-16 to 2019-20
Section 85 and Section 100, including Drs Bag, excluding under co-payment prescriptions

Pharmacy remuneration recognises the cost to the approved pharmacist for the purchase of the medicines; the administration, handling and storage costs entailed in dispensing medicines by the pharmacy (including associated infrastructure costs); and a pharmacist's specialised skills in dispensing the medicines.

	Expenditure for PBS and RPBS Prescriptions	2015-16	2016-17	2017-18	2018-19	2019-20
Price to Pharmacists						
	Ex-Manufacturer Price	\$6,684,653,500	\$7,434,935,265	\$7,091,841,991	\$6,836,615,577	\$6,962,073,670
	Wholesale Mark-up	\$381,961,925	\$378,891,788	\$387,789,430	\$388,998,901	\$409,525,026
	Sub total	\$7,066,615,425	\$7,813,827,053	\$7,479,631,421	\$7,225,614,478	\$7,371,598,696
Administration, Handling and Storage Costs						
	AHI fee*	\$852,204,819	\$858,005,200	\$947,475,648	\$968,930,985	\$990,676,467
	Sub total	\$852,204,819	\$858,005,200	\$947,475,648	\$968,930,985	\$990,676,467
	*Administration, Handling and Infrastructure fee, formerly known as Pharmacy Mark-up					
Pharmacist's Specialised Skills in Dispensing the Medicines						
	Dispensing Fee	\$1,463,471,729	\$1,446,907,289	\$1,478,930,520	\$1,510,512,152	\$1,557,198,213
	Dangerous Drug Fee	\$23,709,571	\$24,846,375	\$25,532,885	\$25,485,028	\$25,561,678
	Wastage	\$3,003,255	\$3,699,720	\$4,294,969	\$4,551,793	\$3,122,365
	Container Fee	\$291,850	\$318,337	\$467,285	\$682,116	\$666,428
	Sub total	\$1,490,476,406	\$1,475,771,721	\$1,509,225,659	\$1,541,231,089	\$1,586,548,684
Other						
	Premium Free Dispensing Incentive	\$108,743,743	\$122,437,929	\$130,516,553	\$150,078,776	\$157,933,476
	Electronic Prescription Fee ²	\$9,042,247	\$8,855,836	\$11,495,215	\$12,141,932	\$13,455,194
	Sub total	\$117,785,989	\$131,293,765	\$142,011,768	\$162,220,708	\$171,388,670
	Total³	\$9,527,082,640	\$10,278,897,739	\$10,078,344,496	\$9,897,997,259	\$10,120,212,518

Summary of Medicines, Wholesalers, and Pharmacy Costs

Medicines cost	\$6,684,653,500	\$7,434,935,265	\$7,091,841,991	\$6,836,615,577	\$6,962,073,670
Wholesale cost	\$381,961,925	\$378,891,788	\$387,789,430	\$388,998,901	\$409,525,026
Pharmacy cost	\$2,460,467,214	\$2,465,070,686	\$2,598,713,075	\$2,672,382,781	\$2,748,613,822
Total	\$9,527,082,640	\$10,278,897,739	\$10,078,344,496	\$9,897,997,259	\$10,120,212,518

1. Table 17 is for PBS and RPBS prescriptions claimed by community pharmacies and friendly societies for both Section 85 and some Section 100 items. It includes Government and patient contributions.

It does not include:

- * Efficient Funding of Chemotherapy (EFC);
- * hospital PBS claims for s85 items (as the report's focus is on community pharmacy);
- * some private hospital HSD claims; and
- * most public hospital HSD claims.

Given what data is and is not included, this table may not be directly comparable to earlier tables in this publication.

2. The Electronic Prescription Fee (EPF) is listed as a program under 6CPA.

3. Health's 2019-20 Annual Report lists the administered expenses for pharmaceutical benefits as \$12.6 billion. The difference between that figure and the total figure above is attributable to:

- * the annual report captures all s85 and s100 accrued expenses (including all HSDs and EFC), while the above data captures all s85 and some s100 data for community pharmacy and friendly societies only (it excludes a number of smaller s100 programs, for example the Opiate Dependence Treatment Program and Remote Area Aboriginal Health Services Program).
- * the annual report data is based on accrual figures, whilst the above data is cash basis;
- * the annual report does not include patient contributions;
- * the annual report data does not include the Premium Free Dispensing Incentive (PFDI) or EPF;
- * the annual report is PBS only and does not include RPBS, whereas the above data includes RPBS, and
- * the annual report also excludes the items in the footnote 1 above.

Table 18: CPA Professional Pharmacy Programs Expenditure, 2019-20

Under the Sixth CPA there were a range of professional programs and services delivered by community pharmacy and pharmacists to support the primary health care needs of consumers. The following table details the funds spent on these programs under CPA in 2019-20 by relevant categories.

Program Type	Actual Expenditure
Rural Pharmacy Maintenance Allowance	\$16,100,000
Rural Pharmacy Workforce Program	\$4,875,000
Medication Management services	\$104,245,000
Medication Adherence services	\$97,466,242
Aboriginal & Torres Strait Islander programs	\$5,109,958
Pharmacy Program administration fees	\$8,665,252
Programs Total	\$236,461,452

Notes:

1. For the Programs administration arrangements for 2019-20, the total funding provided to the Pharmacy Programs Administrator (i.e. Australian Healthcare Associates) was \$236,461,452 (accrual figure). Of this, \$8,665,252 was provided to the Pharmacy Programs Administrator for the purpose of Pharmacy Program administration fees. This means the Pharmacy Program administration fees was 3.66% of the total funds.
2. The Electronic Prescription Fees (EPF) program expenditure is separately reported in Table 17 of the report.
3. Rural Pharmacy Workforce Program, Medication Management services, Medication Adherence Services and Aboriginal and Torres Strait Islander Programs are made up of multiple elements, as per the following tables.

Rural Pharmacy Workforce Program consists of the following elements:	Actual Expenditure
Rural Pharmacist Pre-Reg Inc Allowance Pharmacy - Intern Training Allowance	\$80,000
Emergency Locum Service	\$200,000
Undergraduate Scholarship Internship Pharmacy - Student Placement	\$675,000
Undergraduate Pharmacy-Scholarship Scheme	\$1,200,000
CPE - Continuing Professional Education Allowance	\$300,000
Pharmacy - Rural Administration Support	\$470,000
Rural Pharmacy - Mentor Scheme	\$50,000
Post Intern Incentive Allowance	\$260,000
Undergraduate Scholarship Internship - Intern Incentive Allowance	\$800,000
RPLO	\$840,000
Program Total	\$4,875,000

Medication Management services consist of the following elements:	Actual Expenditure
Diabetes Medscheck and Medscheck	\$45,000,000
Residential Medication Management Review (RMMR)	\$19,000,000
Home Medicines Review (HMR)	\$20,445,000
Clinical Interventions by pharmacists (Pharmacy Practice Incentives)	\$19,800,000
Program Total	\$104,245,000

Medication Adherence services consist of the following elements:	Actual Expenditure
Dose Administration Aids (Pharmacy Practice Incentives)	\$89,266,242
Staged Supply (Pharmacy Practice Incentives)	\$8,200,000
Program Total	\$97,466,242

Aboriginal & Torres Strait Islander Programs consist of the following elements:	Actual Expenditure
Workforce (scholarships)	\$120,000
Workforce (traineeships)	\$160,000
Supporting s100 Remote Aboriginal Area Health Services (RAAHS)	\$2,300,000
Quality Use of Medicines Maximised for Aboriginal and Torres Strait Islander people (QUMAX)	\$2,529,958
Program Total	\$5,109,958

Table 19: Actual Costs of Major Components of CPA*, 2019-20

Component	Expenditure
Pharmacy remuneration	\$ 2,748,613,822
Wholesale remuneration	\$ 409,525,026
Professional programs	\$ 236,461,452
Community Services Obligation (CSO)	\$ 195,220,000
Total	\$ 3,589,820,300

* The current Community Pharmacy Agreement is the 6th CPA.

Notes:

1. Details on how the above figures were identified are provided in the accompanying data tables. The above summary figures should be read in conjunction with the notes provided against each data table.
2. Professional programs and CSO figures are accrual based, as the data used to identify the amounts are based on SAP records, which is an accrual based system.
3. The pharmacy remuneration figure is on a cash basis, as the data used to identify this amount was based on the Line by Line (LBL) data set Health receives from the Services Australia. It was not possible to use the SAP data (accrual basis) for this component, as SAP data does not provide the breakdown between medicine cost and pharmacy remuneration cost elements, whereas the LBL does.

Table 20: Community Services Obligation (CSO) Expenditure, 2019-20

Component	Expenditure
CSO funding pool	\$ 193,931,345
CSO admin	\$ 1,288,655
Total	\$ 195,220,000

The CSO for pharmaceutical wholesalers helps to ensure there are arrangements in place for all Australians to have access to PBS medicines, via their community pharmacy, in a timely manner.

Administration of the CSO funding pool is conducted by the Australian Healthcare Associates under contract to the Department of Health.

PBS Information Line Report 2019-20

The PBS Information Line, established in 1990, is an Australia-wide service which gives information on all aspects of the Pharmaceutical Benefits Scheme to the general public, health professionals, consumer groups, and to other Government Departments and agencies.

During the period 1 July 2019 – 30 June 2020, the information line answered **6,271** calls. This was a decrease of 1.9% from the previous financial year, where 6,390 calls were answered.

Breakdown of calls by month:

Month	Number of calls
July 2019	584
August 2019	597
September 2019	554
October 2019	502
November 2019	502
December 2019	366
January 2020	441
February 2020	431
March 2020	550
April 2020	506
May 2020	550
June 2020	688
Total	6,271

National Diabetes Services Scheme (NDSS)

Since its establishment in 1987, Diabetes Australia (under Diabetes Australia Ltd) has assisted with the administration of the National Diabetes Services Scheme (NDSS) on behalf of the Australian Government. The current agreement runs from 1 July 2016 until 30 June 2021.

The NDSS is managed by the Department of Health through the Diabetes Products Section, in the Pharmacy Branch of the Technology Assessment and Access Division.

The NDSS provides registrants with access to products and services that support the self-management of diabetes at prices subsidised by the Australian Government. Products include syringes and needles, insulin pump consumable products, continuous glucose monitoring products, and blood and urine testing strips, and are available through NDSS Access Points nationally. Access Points mainly comprise community pharmacies plus a very small number of other entities, such as health centres, hospitals and aged care facilities. There are currently over 5,500 NDSS Access Points operating in Australia.

Details of registrant numbers are as follows:

Number of persons with diabetes registered with NDSS						
Year	Insulin using	% change	Non insulin using	% change	Total	% change
1990-91	57,087		12,121		69,208	
1991-92	67,693	18.58%	19,479	60.70%	87,172	25.96%
1992-93	79,010	16.72%	29,476	51.32%	108,486	24.45%
1993-94	90,962	15.13%	42,643	44.67%	133,605	23.15%
1994-95	103,263	13.52%	58,300	36.72%	161,563	20.93%
1995-96	116,275	12.60%	76,772	31.68%	193,047	19.49%
1996-97	129,076	11.01%	98,810	28.71%	227,886	18.05%
1997-98	142,484	10.39%	128,162	29.71%	270,646	18.76%
1998-99	155,943	9.45%	161,678	26.15%	317,621	17.36%
1999-2000	169,306	8.57%	202,549	25.28%	371,855	17.08%
2000-01	182,327	7.69%	246,805	21.85%	429,132	15.40%
2001-02	195,294	7.11%	298,599	20.99%	493,893	15.09%
2002-03	207,632	6.32%	353,825	18.50%	561,457	13.68%
2003-04	219,718	5.82%	409,150	15.64%	628,868	12.01%
2004-05	231,563	5.39%	466,409	13.99%	697,972	10.99%
2005-06	243,023	4.95%	525,365	12.64%	768,388	10.09%
2006-07	255,482	5.13%	588,580	12.03%	844,062	9.85%
2007-08	275,527	7.85%	622,340	5.74%	897,867	6.37%
2008-09	289,940	5.23%	577,567	-7.19%	867,507	-3.37%
2009-10	303,768	7.69%	653,570	8.65%	957,338	8.35%
2010-11	329,142	8.35%	703,575	7.65%	1,032,717	7.87%
2011-12	325,360	-1.15%	712,261	12.35%	1,037,621	0.48%
2012-13	342,349	5.22%	744,511	4.53%	1,086,860	4.75%
2013-14	356,807	4.22%	776,605	4.31%	1,133,412	4.28%

Number of persons with diabetes registered with NDSS						
Year	Insulin using	% change	Non insulin using	% change	Total	% change
2014-15	371,197	4.03%	804,983	3.65%	1,176,180	3.77%
2015-16	383,439	3.3%	827,812	2.84%	1,211,251	3%
2016-17	396,460	3.4%	859,610	3.8%	1,256,070	3.7%
2017-18	403,307	1.7%	873,632	1.6%	1,276,939	1.7%
2018-19	416,269	3.2%	892,801	2.2%	1,309,070	2.52%
2019-20	438,365	5.3%	928,492	4%	1,366,857	4.4%

National Diabetes Services Scheme Expenditure

Total NDSS expenditure for products for the 2019-20 financial year was \$169 million. From 2016-17, NDSS Registrant co-payments are now returned to Consolidated Revenue.

PBS Expenditure and Prescriptions 2019-20

Table 21(a): Historical Pharmaceutical Benefits Scheme Prescriptions (1948-49 to 2019-20)

PRESCRIPTIONS	GENERAL	PENSIONER	CONC	S/NET	TOTAL	DRS BAG	TOTAL - ALL PRESCRIPTIONS
1948/49	280,719				280,719		280,719
1949/50	484,210				484,210		484,210
1950/51	3,758,622				3,758,622		3,758,622
1951/52	6,515,668	1,655,570			8,171,238		8,171,238
1952/53	6,853,937	2,766,947			9,620,884		9,620,884
1953/54	7,004,421	3,453,551			10,457,972		10,457,972
1954/55	9,201,387	4,418,633			13,620,020		13,620,020
1955/56	8,970,890	5,235,013			14,205,903		14,205,903
1956/57	9,045,439	5,580,946			14,626,385		14,626,385
1957/58	10,309,446	6,313,214			16,622,660		16,622,660
1958/59	13,253,168	6,821,578			20,074,746		20,074,746
1959/60	16,624,342	8,028,968			24,653,310		24,653,310
1960/61	20,489,065	10,727,570			31,216,635		31,216,635
1961/62	26,050,370	11,664,036			37,714,406		37,714,406
1962/63	29,517,810	12,674,230			42,192,040		42,192,040
1963/64	31,039,624	13,317,273			44,356,897		44,356,897
1964/65	33,714,429	13,841,372			47,555,801		47,555,801
1965/66	35,084,551	14,908,393			49,992,944		49,992,944
1966/67	36,750,907	16,936,435			53,687,342		53,687,342
1967/68	37,053,212	18,369,634			55,422,846		55,422,846
1968/69	40,453,366	19,954,471			60,407,837		60,407,837
1969/70	44,071,198	21,504,166			65,575,364		65,575,364
1970/71	48,971,406	22,515,117			71,486,523		71,486,523
1971/72	48,491,692	23,950,503			72,442,195		72,442,195
1972/73	49,115,497	25,560,576			74,676,073		74,676,073
1973/74	59,499,823	27,788,036			87,287,859		87,287,859
1974/75	67,350,637	30,323,662			97,674,299		97,674,299
1975/76	67,722,534	33,394,757			101,117,291		101,117,291
1976/77	56,099,277	33,606,128			89,705,405		89,705,405
1977/78	57,751,904	35,414,619			93,166,523		93,166,523
1978/79	53,553,036	39,409,489			92,962,525		92,962,525
1979/80	46,624,224	42,450,386			89,074,610		89,074,610
1980/81	47,619,120	46,778,057			94,397,177		94,397,177
1981/82	53,834,648	49,739,756			103,574,404		103,574,404
1982/83	50,078,929	52,529,929	2,931,462		105,540,320		105,540,320
1983/84	41,938,964	56,491,285	9,954,995		108,385,244		108,385,244
1984/85	50,690,275	60,069,806	10,068,817		120,828,898		120,828,898
1985/86	46,334,279	63,191,858	10,315,799		119,841,936		119,841,936
1986/87	28,762,909	64,243,148	9,755,680	2	102,761,737		102,761,737
1987/88	12,339,360	81,041,242	7,520,752	15,059,811	100,901,354		100,901,354
1988/89	14,078,934	78,283,599	8,223,231	11,925,271	100,585,764		100,585,764
1989/90	15,361,517	80,761,310	8,856,241	11,725,474	104,979,068		104,979,068
1990/91	10,608,974	36,868,817	36,588,405	11,675,164	95,741,360	558,899	96,300,259

Notes
 -Dr's Bag prior to 90/91 included in General, from 90/91 included in miscellaneous expenditure
 -For 90/91 Concessional includes 'old' (prior to 1/11/90) prescriptions and 'new' (post 1/11/90) concessional category
 -Exclude under co-payment prescriptions

Safety Net
 Prior to 90/91 S/net for Gen & Concess is included in pensioner. In 90/91 free s/net is in both pensioner and s/net categories

PBS Expenditure and Prescriptions 2019-20

Table 21(a): Historical Pharmaceutical Benefits Scheme Prescriptions (1948-49 to 2019-20) Continued

PRESCRIPTIONS	GENERAL				CONCESSIONAL			TOTAL PRESCRIPTIONS	DRS BAG	TOTAL- ALL PRESCRIPTIONS
	NSN	S/Net 1	S/NET 2	TOTAL	NSN	S/NET	TOTAL			
1991/92	8,266,835	2,340,145	1,092,314	11,699,294	67,331,793	14,428,608	81,760,401	93,459,695	660,459	94,120,154
1992/93	10,260,426	3,917,022	2,800,496	16,977,944	71,756,325	16,757,840	88,514,165	105,492,109	689,508	106,181,617
1993/94	11,451,148	4,259,245	3,087,943	18,798,336	77,536,126	18,003,354	95,539,480	114,337,816	704,227	115,042,043
1994/95	13,491,364	4,695,314	2,072	18,188,750	82,400,588	17,457,008	99,857,596	118,046,346	674,331	118,720,677
1995/96	14,212,731	5,488,957	52	19,701,740	85,604,215	18,898,907	104,503,122	124,204,862	683,420	124,888,282
1996/97	14,709,601	3,082,843	14	17,792,458	85,965,797	19,676,007	105,641,804	123,434,262	665,301	124,099,563
1997/98	14,087,393	3,945,591	17	18,033,001	86,389,807	20,060,505	106,450,312	124,483,313	628,496	125,111,809
1998/99	15,153,975	4,111,091		19,265,066	88,475,327	20,608,073	109,083,400	128,348,466	572,753	128,921,219
1999/00	16,296,703	3,928,760		20,225,463	94,281,872	23,078,282	117,360,154	137,585,617	496,306	138,081,923
2000/01	18,526,141	4,340,364		22,866,505	99,285,160	25,420,114	124,705,274	147,571,779	478,999	148,050,778
2001/02	19,292,104	4,813,038		24,105,142	102,018,211	28,406,603	130,424,814	154,529,956	448,283	154,978,239
2002/03	20,694,131	5,188,492		25,882,623	101,459,056	31,177,491	132,636,547	158,519,170	437,516	158,956,686
2003/04	22,443,338	5,544,618		27,987,956	104,619,866	32,827,303	137,447,169	165,435,125	426,976	165,862,101
2004/05	22,194,451	6,209,302		28,403,753	105,377,946	36,095,311	141,473,257	169,877,010	402,492	170,279,502
2005/06	20,917,523	5,910,828		26,828,351	105,152,486	35,945,690	141,098,176	167,926,527	396,088	168,322,615
2006/07	19,871,669	4,710,422		24,582,091	110,917,202	32,675,864	143,593,066	168,175,157	360,362	168,535,519
2007/08	19,607,454	4,553,340		24,160,794	113,118,234	33,680,813	146,799,047	170,959,841	336,182	171,296,023
2008-09	20,746,777	5,580,636		26,327,413	119,906,347	35,234,371	155,140,718	181,468,131	367,996	181,836,127
2009-10	21,226,750	4,763,435		25,990,185	122,832,364	34,756,644	157,589,008	183,579,193	332,344	183,911,537
2010-11	21,032,398	4,943,233		25,975,631	125,446,923	36,381,986	161,828,909	187,804,540	337,715	188,142,255
2011-12	21,239,413	4,820,643		26,060,056	130,441,952	38,046,697	168,488,649	194,548,705	324,424	194,873,129
2012-13	19,323,589	4,371,046		23,694,635	133,646,630	39,611,994	173,258,624	196,953,259	352,123	197,305,382
2013-14	18,050,307	4,052,529		22,102,836	145,340,393	42,009,011	187,349,404	209,452,240	363,763	209,816,003
2014-15	15,902,515	3,544,902		19,447,417	147,979,717	44,277,679	192,257,396	211,704,813	380,376	212,085,189
2015-16	13,770,978	3,180,897		16,951,875	146,529,394	44,119,861	190,649,255	207,601,130	388,859	207,989,989

New Series	GENERAL			CONCESSIONAL			TOTAL PBS	DRS BAG	MISC and S100	TOTAL - ALL PRESCRIPTIONS
	NSN	S/Net	TOTAL	NSN	S/Net	TOTAL				
2016-17	12,334,542	2,699,345	15,033,887	144,336,986	36,045,418	180,382,404	195,416,291	394,352	2,560,813	198,371,456
2017-18	13,332,423	2,616,813	15,949,236	148,018,925	37,047,645	185,066,570	201,015,806	398,051	2,645,790	204,059,647
2018-19	13,490,749	2,637,491	16,128,240	148,244,490	37,499,894	185,744,384	201,872,624	402,827	2,813,028	205,088,479
2019-20	13,873,735	2,577,950	16,451,685	148,326,789	40,280,313	188,607,102	205,058,787	418,823	2,992,062	208,469,672

CONC: Concessional

S/NET: Safety Net

PENSIONER: Before 1 November 1990 pensioners received PBS drugs free of charge.

NSN: Non Safety Net

S/NET 1, S/NET 2: Between 1991 and 1993 there were 2 tiers in the general safety net. Some prescriptions supplied during this period were processed in 1994 or after and the two tier structure applied to these.

MISC and SECT 100: Section 100 programs.

Note: From 2016-17, the data is reported by the date that a prescription was supplied. Prior to this, prescriptions were reported by the date that they were processed by the Services Australia.

Table 21(b): Historical Pharmaceutical Benefits Scheme Expenditure (1948-49 to 2019-20)

YEAR	GOVERNMENT EXPENDITURE					SUB TOTAL	HOSP & MISC		TOTAL GOVT		PATIENT CONTRIBUTION		TOTAL COST	TOTAL with
	GEN	CONC	PENS	SAFETY NET			MISC		COST	GEN	CON	TOTAL	PRESCRIPTIONS	S.100 & Misc
1948/49	132,536					132,536	165,538		298,074			-	132,536	298,074
1949/50	346,682					346,682	262,696		609,378			-	346,682	609,378
1950/51	5,453,558					5,453,558	406,768		5,860,326			-	5,453,558	5,860,326
1951/52	13,424,294		715,264			14,139,558	1,230,536		15,370,094			-	14,139,558	15,370,094
1952/53	12,399,568		1,457,316			13,856,884	573,734		14,430,618			-	13,856,884	14,430,618
1953/54	14,320,372		2,021,560			16,341,932	2,116,894		18,458,826			-	16,341,932	18,458,826
1954/55	16,303,940		2,589,672			18,893,612	2,585,322		21,478,934			-	18,893,612	21,478,934
1955/56	18,061,092		3,015,920			21,077,012	2,697,858		23,774,870			-	21,077,012	23,774,870
1956/57	17,171,670		3,586,200			20,757,870	2,675,776		23,433,646			-	20,757,870	23,433,646
1957/58	22,826,484		4,246,490			27,072,974	2,995,004		30,067,978			-	27,072,974	30,067,978
1958/59	33,112,570		5,034,746			38,147,316	3,798,278		41,945,594			-	38,147,316	41,945,594
1959/60	36,714,806		7,148,446			43,863,252	4,808,090		48,671,342	1,890,756		1,890,756	45,754,008	50,562,098
1960/61	34,282,496		14,676,698			48,959,194	6,803,248		55,762,442			10,324,740	59,283,934	66,087,182
1961/62	44,632,488		18,194,996			62,827,484	7,552,282		70,379,766			13,007,776	75,835,260	83,387,542
1962/63	47,093,026		19,830,750			66,923,776	9,986,382		76,910,158			14,742,448	81,666,224	91,652,606
1963/64	46,460,998		20,601,714			67,062,712	11,775,958		78,838,670			15,573,804	82,636,516	94,412,474
1964/65	48,929,748		21,564,420			70,494,168	11,708,442		82,202,610			16,841,354	87,335,522	99,043,964
1965/66	53,078,046		24,071,127			77,149,173	14,634,501		91,783,674			17,481,228	94,630,401	109,264,902
1966/67	56,655,939		29,280,268			85,936,207	15,344,592		101,280,799			18,347,036	104,283,243	119,627,835
1967/68	56,800,249		32,115,335			88,915,584	16,218,859		105,134,443			18,504,345	107,419,929	123,638,788
1968/69	64,024,983		36,609,257			100,634,240	17,739,118		118,373,358			20,129,402	120,763,642	138,502,760
1969/70	73,227,887		41,068,702			114,296,589	22,421,727		136,718,316			21,941,691	136,238,280	158,660,007
1970/71	88,176,385		45,180,856			133,357,241	26,917,666		160,274,907			24,384,028	157,741,269	184,658,935
1971/72	90,061,869		52,005,350			142,067,219	31,201,229		173,268,448			35,466,642	177,533,861	208,735,090
1972/73	87,431,438		58,139,459			145,570,897	32,061,691		177,632,588			48,640,243	194,211,140	226,272,831
1973/74	108,066,351		66,802,821			174,869,172	43,426,672		218,295,844			59,015,335	233,884,507	277,311,179
1974/75	131,341,320		80,586,986			211,928,306	50,368,781		262,297,087			66,827,982	278,756,288	329,125,069
1975/76	149,033,245		107,317,318			256,350,563	27,490,706		283,841,269			95,244,660	351,595,223	379,085,929
1976/77	111,077,507		115,201,775			226,279,282	8,623,582		234,902,864			111,676,421	337,955,703	346,579,285
1977/78	118,303,375		127,911,837			246,215,212	9,832,410		256,047,622			115,025,169	361,240,381	371,072,791
1978/79	110,425,438		151,125,681			261,551,119	9,767,502		271,318,621			129,540,759	391,091,878	400,859,380
1979/80	101,185,503		166,361,113			267,546,616	7,088,452		274,635,068			123,418,168	390,964,784	398,053,236
1980/81	107,903,558		191,043,798			298,947,356	10,267,063		309,214,419			129,923,272	428,870,628	439,137,691
1981/82	139,547,856		239,894,493			379,442,349	11,377,241		390,819,590			157,957,635	537,399,984	548,777,225
1982/83	131,773,044	11,100,973	272,707,495			415,581,512	14,685,428		430,266,940		5,882,844	176,500,374	592,081,886	606,767,314
1983/84	114,638,367	39,276,732	317,819,660			471,734,759	17,490,165		489,224,924		19,975,026	186,018,473	657,753,232	675,243,397
1984/85	142,439,672	43,266,712	356,213,948			541,920,332	17,877,162		559,797,494		20,208,116	221,350,358	763,270,690	781,147,852
1985/86	138,365,148	50,172,930	408,026,507			596,564,585	19,258,116		615,822,701		20,715,057	243,001,453	839,566,038	858,824,154
1986/87	140,571,611	59,738,152	514,236,037		12	714,545,800	23,457,302		738,003,102		167,130,307	22,048,299	893,724,406	927,181,708
1987/88	111,740,361	51,574,897	747,536,316	159,418,168		910,851,574	35,612,019		946,463,593		117,938,301	18,839,286	1,047,629,161	1,083,241,180
1988/89	132,040,607	63,272,252	795,027,196	138,531,290		990,340,055	33,194,842		1,023,534,897		147,704,171	20,603,194	1,158,647,420	1,191,842,262
1989/90	170,039,203	74,757,555	890,753,297	150,064,548		1,135,550,055	43,852,385		1,179,402,440		162,587,554	22,174,539	1,320,312,148	1,364,164,533
1990/91	157,783,001	342,720,328	428,743,821	580,709,870		1,094,463,443	64,798,247		1,159,261,690		132,120,868	91,672,986	2,237,935,854	2,370,055,544

Note -Free Pensioner category removed from 1 Nov 90, \$2.50 copayment and free safety net introduced for all Concessionals
 -Dr's Bag prior to 90/91 included in General
 from 90/91 (\$12,255,895) included in Misc

Safety Net -For Gen & Conc prior to 90/91 is included in Pensioner
 -For 90/91 S/net includes both pre & post 1/11/90 free Snet
 -Gen S/net 1 included in Concess in 90/91
 -Gen S/net 2 (free) 1 Jan 91 to 31 Dec 93

Table 21(b): Historical Pharmaceutical Benefits Scheme Expenditure (1948-49 to 2019-20) Continued

GOVERNMENT EXPENDITURE - \$-											
	GENERAL-NSN	GEN S/Net 1	GEN S/Net 2	TOTAL GEN	CONC - NSN	CONC S/Net	TOTAL CONC	TOTAL FOR PBS	MISC and SECT 100	TOTAL GOVT EXP	
1991/92	160,765,548	36,400,482	18,911,584	216,077,614	708,413,833	195,000,082	903,413,915	1,119,491,529	100,877,826	1,220,369,355	
1992/93	188,270,160	65,845,466	53,077,875	307,193,500	844,972,301	251,249,539	1,096,221,840	1,403,415,340	101,552,426	1,504,967,766	
1993/94	224,675,364	78,832,510	63,861,452	367,369,326	1,019,651,580	297,597,894	1,317,249,474	1,684,618,800	116,696,888	1,801,315,688	
1994/95	290,765,883	93,406,668	38,565	384,211,116	1,194,999,580	302,502,892	1,497,502,472	1,881,713,588	109,621,215	1,991,334,803	
1995/96	343,025,066	118,655,085	785	461,680,936	1,369,432,585	360,130,508	1,729,563,093	2,191,244,029	135,473,133	2,326,717,162	
1996/97	392,246,135	72,831,781	210	465,078,126	1,465,657,637	401,814,359	1,867,471,996	2,332,550,122	205,545,012	2,538,095,134	
1997/98	411,856,192	98,613,376	465	510,470,033	1,576,058,096	439,989,321	2,016,047,417	2,526,517,450	258,950,240	2,785,467,690	
1998/99	469,042,094	106,618,491	-	575,660,585	1,739,535,268	467,079,112	2,206,614,380	2,782,274,965	287,469,135	3,069,744,100	
1999/00	521,018,128	107,012,848	-	628,030,976	2,000,636,597	547,829,734	2,548,466,331	3,176,497,307	311,727,262	3,488,224,569	
2000/01	662,099,200	128,173,886	-	790,273,086	2,359,650,038	660,303,947	3,019,953,985	3,810,227,071	347,901,802	4,158,128,873	
2001/02	691,204,687	148,498,520	-	839,703,207	2,569,555,585	778,411,796	3,347,967,381	4,187,670,588	396,386,682	4,584,057,270	
PATIENT CONTRIBUTION - \$-											
	GENERAL-NSN	GEN S/Net 1	GEN S/Net 2	TOTAL GEN	CONC - NSN	CONC S/Net	TOTAL CONC	TOTAL FOR PBS	TOTAL COST TOTAL FOR PRESCRIPTIONS	MISC and SECT 100	TOTAL
1991/92	128,988,053	6,043,066	-	135,031,119	173,201,117	-	173,201,117	308,232,236	1,427,723,765	100,877,826	1,528,601,591
1992/93	162,967,769	10,202,578	-	173,170,347	186,726,902	-	186,726,902	359,897,249	1,763,312,589	101,552,426	1,864,865,015
1993/94	183,012,475	11,074,025	-	194,086,500	201,596,301	-	201,596,301	395,682,801	2,080,301,601	116,696,888	2,196,998,489
1994/95	218,094,751	12,207,816	-	230,302,567	214,241,512	-	214,241,512	444,544,079	2,326,257,667	109,621,215	2,435,878,882
1995/96	237,239,817	14,278,699	-	251,518,516	226,583,554	-	226,583,554	478,102,070	2,669,346,099	135,473,133	2,804,819,232
1996/97	269,715,066	8,375,980	-	278,091,046	252,104,590	-	252,104,590	530,195,636	2,862,745,758	205,545,012	3,068,290,770
1997/98	281,739,252	12,625,016	-	294,364,268	276,440,026	-	276,440,026	570,804,294	3,097,321,744	258,950,240	3,356,271,984
1998/99	305,064,052	13,155,417	-	318,219,469	283,117,963	-	283,117,963	601,337,432	3,383,612,397	287,469,135	3,671,081,532
1999/00	333,003,549	12,584,337	-	345,587,886	306,183,001	-	306,183,001	651,770,887	3,828,268,194	311,727,262	4,139,995,456
2000/01	392,432,536	14,353,837	-	406,786,373	337,379,028	-	337,379,028	744,165,401	4,554,392,472	347,901,802	4,902,294,274
2001/02	426,974,621	16,864,336	-	443,838,957	362,237,529	-	362,237,529	806,076,486	4,993,747,074	396,386,682	5,390,133,756
DOCTOR'S BAG - \$ - (included in miscellaneous from 90/91)											
1990/91	12,255,895	-	-	12,255,895	-	-	-	-	-	-	-
1991/92	14,514,725	-	-	14,514,725	-	-	-	-	-	-	-
1992/93	16,082,655	-	-	16,082,655	-	-	-	-	-	-	-
1993/94	16,679,933	-	-	16,679,933	-	-	-	-	-	-	-
1994/95	15,674,643	-	-	15,674,643	-	-	-	-	-	-	-
1995/96	16,202,098	-	-	16,202,098	-	-	-	-	-	-	-
1996/97	15,769,173	-	-	15,769,173	-	-	-	-	-	-	-
1997/98	14,953,823	-	-	14,953,823	-	-	-	-	-	-	-
1998/99	13,370,491	-	-	13,370,491	-	-	-	-	-	-	-
1999/00	10,754,395	-	-	10,754,395	-	-	-	-	-	-	-
2000/01	10,343,534	-	-	10,343,534	-	-	-	-	-	-	-
2001/02	9,803,682	-	-	9,803,682	-	-	-	-	-	-	-

note- from 91/92 all figures are sourced from the Services Australia processing where available
 -miscellaneous and section 100 expenditure sourced from Department of Health and Services Australia payments

S/NET 1, S/NET 2: Between 1991 and 1993 there were 2 tiers in the general safety net. Some prescriptions supplied during this period were processed in 1994 or after and the two tier structure applied to these.

CONC: Concessional
 S/Net: Safety Net
 GEN: General
 NSN: Non Safety Net

MISC and SECT 100: Drugs provided through special programs and hospitals; Section 100 drugs.
 HOSP & MISC: Drugs provided through special programs and hospitals; Section 100 drugs.
 PENS: Before 1 November 1990 pensioners received PBS drugs free of charge.

Table 21(b): Historical Pharmaceutical Benefits Scheme Expenditure (1948-49 to 2019-20) Continued

GOVERNMENT EXPENDITURE - \$-										
	GENERAL-NSN	GEN S/Net	TOTAL GEN	CONC - NSN	CONC S/Net	TOTAL CONC	TOTAL FOR PBS	MISC and SECT 100	TOTAL GOVT EXP	
2002/03	\$747,049,026	\$169,693,390	\$916,742,416	\$2,741,874,040	\$907,119,434	\$3,648,993,474	\$4,565,735,890	\$477,352,298	\$5,043,088,188	
2003/04	\$824,130,608	\$190,682,979	\$1,014,813,587	\$2,972,331,634	\$1,004,522,779	\$3,976,854,413	\$4,991,668,000	\$570,500,000	\$5,562,168,000	
2004/05	\$850,690,906	\$222,668,220	\$1,073,359,125	\$3,077,033,801	\$1,145,497,231	\$4,222,531,032	\$5,295,890,157	\$668,500,000	\$5,964,390,157	
2005/06	\$850,095,680	\$216,246,563	\$1,066,342,242	\$3,145,480,431	\$1,172,502,111	\$4,317,982,542	\$5,384,324,784	\$764,000,000	\$6,148,324,784	
2006/07	\$890,275,536	\$174,127,771	\$1,064,403,307	\$3,333,875,949	\$1,067,478,074	\$4,401,354,023	\$5,465,757,330	\$886,500,000	\$6,352,257,330	
2007/08	\$1,039,451,749	\$173,499,550	\$1,212,951,299	\$3,561,294,283	\$1,137,925,393	\$4,699,219,676	\$5,912,170,974	\$975,500,000	\$6,887,670,974	
2008/09	\$1,220,279,806	\$217,487,483	\$1,437,767,290	\$3,909,584,010	\$1,216,050,241	\$5,125,634,250	\$6,563,401,540	\$1,081,400,000	\$7,644,801,540	
2009/10	\$1,339,182,210	\$199,599,002	\$1,538,781,212	\$4,220,391,341	\$1,259,719,602	\$5,480,110,943	\$7,018,892,155	\$1,232,400,000	\$8,251,292,155	
2010-11	\$1,412,781,352	\$211,944,918	\$1,624,726,270	\$4,367,739,898	\$1,330,682,636	\$5,698,422,533	\$7,323,148,803	\$1,335,500,000	\$8,658,648,803	
2011-12	\$1,453,773,280	\$208,167,009	\$1,661,940,288	\$4,476,104,435	\$1,390,159,396	\$5,866,263,831	\$7,528,204,119	\$1,473,700,000	\$9,001,904,119	
2012-13	\$1,339,654,102	\$169,213,844	\$1,508,867,945	\$4,209,086,581	\$1,351,536,398	\$5,560,622,979	\$7,069,490,924	\$1,812,600,000	\$8,882,090,924	
PATIENT CONTRIBUTION	-\$-							TOTAL COST		TOTAL
	GENERAL-NSN	GEN S/Net	TOTAL GEN	CONC - NSN	CONC S/Net	TOTAL CONC	TOTAL FOR PBS	TOTAL - FOR PRESCRIPTIONS	MISC and SECT 100	
2002/03	\$470,306,937	\$18,698,099	\$489,005,036	\$370,426,183	-	\$370,426,183	\$859,431,219	\$5,425,167,109	\$477,352,298	\$5,902,519,407
2003/04	\$524,763,848	\$20,538,514	\$545,302,362	\$392,513,143	-	\$392,513,143	\$937,815,505	\$5,929,483,505	\$570,500,000	\$6,499,983,505
2004/05	\$572,963,103	\$23,742,733	\$596,705,836	\$443,930,641	-	\$443,930,641	\$1,040,636,477	\$6,336,526,634	\$668,500,000	\$7,005,026,634
2005/06	\$606,897,345	\$27,199,070	\$634,096,415	\$489,173,277	-	\$489,173,277	\$1,123,269,692	\$6,507,594,476	\$764,000,000	\$7,271,594,476
2006/07	\$596,483,266	\$22,154,622	\$618,637,888	\$532,682,972	-	\$532,682,972	\$1,151,320,859	\$6,617,078,189	\$886,500,000	\$7,503,578,189
2007/08	\$607,183,393	\$22,323,024	\$629,506,417	\$559,962,883	-	\$559,962,883	\$1,189,469,300	\$7,101,640,274	\$975,500,000	\$8,077,140,274
2008/09	\$663,449,571	\$27,928,829	\$691,378,400	\$617,378,323	-	\$617,378,323	\$1,308,756,723	\$7,872,158,263	\$1,081,400,000	\$8,953,558,263
2009/10	\$701,961,714	\$25,253,391	\$727,215,106	\$656,949,638	-	\$656,949,638	\$1,384,164,743	\$8,403,056,898	\$1,232,400,000	\$9,635,456,898
2010-11	\$707,968,006	\$26,706,262	\$734,674,267	\$689,108,592	-	\$689,108,592	\$1,423,782,860	\$8,746,931,663	\$1,335,500,000	\$10,082,431,663
2011-12	\$735,994,339	\$27,003,502	\$762,997,841	\$742,139,779	-	\$742,139,779	\$1,505,137,620	\$9,033,341,739	\$1,473,700,000	\$10,507,041,739
2012-13	\$689,036,554	\$25,352,649	\$714,389,203	\$781,002,893	-	\$781,002,893	\$1,495,392,096	\$8,564,883,021	\$1,812,600,000	\$10,377,483,021
Doctor's Bag - \$ - (included in miscellaneous from 90/91)										
2002/03	\$9,510,606									
2003/04	\$9,408,669									
2004/05	\$9,365,803									
2005/06	\$10,063,803									
2006/07	\$10,698,205									
2007/08	\$13,468,779									
2008/09	\$14,533,302									
2009/10	\$13,571,776									
2010-11	\$14,228,520									
2011-12	\$12,974,506									
2012-13	\$14,755,085									

note- from 91/92 all figures are sourced from the Services Australia processing where available
 -miscellaneous and section 100 expenditure sourced from Department of Health and Services Australia payments

S/NET 1, S/NET 2: Between 1991 and 1993 there were 2 tiers in the general safety net. Some prescriptions supplied during this period were processed in 1994 or after and the two tier structure applied to these.

CONC: Concessional

S/Net: Safety Net

GEN: General

NSN: Non Safety Net

MISC and SECT 100: Drugs provided through special programs and hospitals; Section 100 drugs.

HOSP & MISC: Drugs provided through special programs and hospitals; Section 100 drugs.

PENS: Before 1 November 1990 pensioners received PBS drugs free of charge.

Table 21(b): Pharmaceutical Benefits Scheme History - Government Expenditure & Patient Contribution, 1948-49 to 2019-20 Continued

GOVERNMENT EXPENDITURE - \$-										
	GENERAL-NSN	GEN S/Net	TOTAL GEN	CONC - NSN	CONC S/Net	TOTAL CONC	TOTAL FOR PBS	MISC and SECT 100	TOTAL GOVT EXP	
2013-14	\$1,429,860,300	\$154,692,449	\$1,584,552,749	\$4,319,414,670	\$1,388,583,542	\$5,707,998,212	\$7,292,550,961	\$2,033,900,000	\$9,326,450,961	
2014-15	\$1,463,256,600	\$129,523,975	\$1,592,780,575	\$4,123,482,128	\$1,380,416,342	\$5,503,898,470	\$7,096,679,044	\$2,183,101,118	\$9,279,780,162	
2015-16	\$1,785,357,915	\$118,821,879	\$1,904,179,793	\$4,630,980,302	\$1,413,858,158	\$6,044,838,460	\$7,949,018,254	\$2,752,825,107	\$10,701,843,361	
New Series	GENERAL-NSN	GEN S/Net	TOTAL GEN	CONC - NSN	CONC S/Net	TOTAL CONC	TOTAL PBS	DRS BAG	MISC and S100	TOTAL GOVT EXP
2016-17	\$2,088,188,915	\$103,984,977	\$2,192,173,892	\$5,315,606,905	\$1,204,716,252	\$6,520,323,157	\$8,712,497,049	\$16,718,674	\$3,043,936,194	\$11,773,151,917
2017-18	\$1,981,594,072	\$101,429,150	\$2,083,023,223	\$5,127,198,161	\$1,236,961,876	\$6,364,160,037	\$8,447,183,260	\$16,568,617	\$3,139,112,049	\$11,602,863,926
2018-19	\$2,005,253,340	\$102,355,665	\$2,107,609,004	\$4,844,366,564	\$1,243,669,704	\$6,088,036,267	\$8,195,645,272	\$16,002,440	\$3,487,069,944	\$11,698,717,656
2019-20	\$2,142,135,695	\$104,447,648	\$2,246,583,343	\$4,918,980,015	\$1,370,238,848	\$6,289,218,863	\$8,535,802,207	\$16,858,042	\$3,954,440,736	\$12,507,100,984
PATIENT CONTRIBUTION - \$-										
	GENERAL-NSN	GEN S/Net	TOTAL GEN	CONC - NSN	CONC S/Net	TOTAL CONC	TOTAL FOR PBS	TOTAL COST TOTAL - FOR PRESCRIPTIONS	MISC and SECT 100	TOTAL
2013-14	\$656,913,329	\$23,915,012	\$680,828,341	\$864,226,399	-	\$864,226,399	\$1,545,054,740	\$8,837,605,701	\$2,033,900,000	\$10,871,505,701
2014-15	\$567,399,905	\$21,021,090	\$588,420,995	\$877,483,279	-	\$877,483,279	\$1,465,904,274	\$8,562,583,318	\$2,183,101,118	\$10,745,684,436
2015-16	\$494,124,051	\$19,115,443	\$513,239,494	\$880,965,644	-	\$880,965,644	\$1,394,205,138	\$9,343,223,391	\$2,752,825,107	\$12,096,048,498
New Series	GENERAL-NSN	GEN S/Net	TOTAL GEN	CONC - NSN	CONC S/Net	TOTAL CONC	TOTAL PBS	TOTAL COST *	MISC and S100	TOTAL EXP **
2016-17	\$444,029,285	\$16,448,625	\$460,477,909	\$880,418,081	-	\$880,418,081	\$1,340,895,990	\$10,053,393,039	\$38,361,124	\$13,152,409,031
2017-18	\$484,120,874	\$16,143,997	\$500,264,871	\$915,055,636	-	\$915,055,636	\$1,415,320,507	\$9,862,503,767	\$40,183,135	\$13,058,367,568
2018-19	\$494,513,005	\$16,477,196	\$510,990,200	\$929,032,414	-	\$929,032,414	\$1,440,022,615	\$9,635,667,887	\$44,642,304	\$13,183,382,575
2019-20	\$512,660,643	\$16,287,445	\$528,948,088	\$942,085,948	-	\$942,085,948	\$1,471,034,036	\$10,006,836,242	\$48,802,754	\$14,026,937,774
TOTAL COST *	Total cost for Section 85 (Patient payment + Government benefit)									
TOTAL EXP **	Total PBS Expenditure, Section 85, Section 100 and Drs Bag (Patient payment + Government benefit)									
Doctor's Bag - \$ - (included in miscellaneous from 90/91)										
2013-14	\$16,009,408									
2014-15	\$16,340,036									
2015-16	\$15,887,150									
2016-17	\$16,718,674									
2017-18	\$16,568,617									
2018-19	\$16,002,440									
2019-20	\$16,858,042									

Notes:

From 2016-17, the data is reported by the date that a prescription was supplied. Prior to this, Government expenditure and patient contributions were reported by the date that the prescriptions were processed by the Services Australia.

From 1991-92 all figures are sourced from the Services Australia processing where available

Miscellaneous and section 100 expenditure sourced from Department of Health and Services Australia payments

S/NET 1, S/NET 2: Between 1991 and 1993 there were 2 tiers in the general safety net. Some prescriptions supplied during this period were processed in 1994 or after and the two tier structure applied to these.

CONC: Concessional

S/Net: Safety Net

GEN: General

NSN: Non Safety Net

MISC and SECT 100: Section 100 programs, other ungrouped expenditure

HOSP & MISC: Drugs provided through special programs and hospitals; Section 100 drugs.

PENS: Before 1 November 1990 pensioners received PBS drugs free of charge.